<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" article-type="research-article" dtd-version="2.3" xml:lang="EN">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">Front. Oncol.</journal-id>
<journal-title>Frontiers in Oncology</journal-title>
<abbrev-journal-title abbrev-type="pubmed">Front. Oncol.</abbrev-journal-title>
<issn pub-type="epub">2234-943X</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.3389/fonc.2021.762063</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Oncology</subject>
<subj-group>
<subject>Original Research</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>Association Analysis Between the Functional Single Nucleotide Variants in miR-146a, miR-196a-2, miR-499a, and miR-612 With Acute Lymphoblastic Leukemia</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Jim&#xe9;nez-Morales</surname>
<given-names>Silvia</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="author-notes" rid="fn001">
<sup>*</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/959423"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>N&#xfa;&#xf1;ez-Enr&#xed;quez</surname>
<given-names>Juan Carlos</given-names>
</name>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/980779"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Cruz-Islas</surname>
<given-names>Jazm&#xed;n</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Bekker-M&#xe9;ndez</surname>
<given-names>Vilma Carolina</given-names>
</name>
<xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/938627"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Jim&#xe9;nez-Hern&#xe1;ndez</surname>
<given-names>Elva</given-names>
</name>
<xref ref-type="aff" rid="aff4">
<sup>4</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/382198"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Medina-Sanson</surname>
<given-names>Aurora</given-names>
</name>
<xref ref-type="aff" rid="aff5">
<sup>5</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/1045093"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Olarte-Carrillo</surname>
<given-names>Irma</given-names>
</name>
<xref ref-type="aff" rid="aff6">
<sup>6</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/1480066"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Mart&#xed;nez-Tovar</surname>
<given-names>Adolfo</given-names>
</name>
<xref ref-type="aff" rid="aff6">
<sup>6</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/1477322"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Flores-Lujano</surname>
<given-names>Janet</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/1012962"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Ram&#xed;rez-Bello</surname>
<given-names>Julian</given-names>
</name>
<xref ref-type="aff" rid="aff7">
<sup>7</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/738216"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>P&#xe9;rez-Sald&#xed;var</surname>
<given-names>Mar&#xed;a Luisa</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/1077194"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Mart&#xed;n-Trejo</surname>
<given-names>Jorge Alfonso</given-names>
</name>
<xref ref-type="aff" rid="aff8">
<sup>8</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>P&#xe9;rez-Lorenzana</surname>
<given-names>H&#xe9;ctor</given-names>
</name>
<xref ref-type="aff" rid="aff9">
<sup>9</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Amador-S&#xe1;nchez</surname>
<given-names>Raquel</given-names>
</name>
<xref ref-type="aff" rid="aff10">
<sup>10</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/1076585"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Mora-R&#xed;os</surname>
<given-names>Felix Gustavo</given-names>
</name>
<xref ref-type="aff" rid="aff11">
<sup>11</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Pe&#xf1;aloza-Gonz&#xe1;lez</surname>
<given-names>Jos&#xe9; Gabriel</given-names>
</name>
<xref ref-type="aff" rid="aff12">
<sup>12</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Duarte-Rodr&#xed;guez</surname>
<given-names>David Aldebar&#xe1;n</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Torres-Nava</surname>
<given-names>Jos&#xe9; Refugio</given-names>
</name>
<xref ref-type="aff" rid="aff13">
<sup>13</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Flores-Bautista</surname>
<given-names>Juan Eduardo</given-names>
</name>
<xref ref-type="aff" rid="aff14">
<sup>14</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Espinosa-Elizondo</surname>
<given-names>Rosa Martha</given-names>
</name>
<xref ref-type="aff" rid="aff15">
<sup>15</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Rom&#xe1;n-Zepeda</surname>
<given-names>Pedro Francisco</given-names>
</name>
<xref ref-type="aff" rid="aff16">
<sup>16</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Flores-Villegas</surname>
<given-names>Luz Victoria</given-names>
</name>
<xref ref-type="aff" rid="aff17">
<sup>17</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Tamez-G&#xf3;mez</surname>
<given-names>Edna Liliana</given-names>
</name>
<xref ref-type="aff" rid="aff18">
<sup>18</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>L&#xf3;pez-Garc&#xed;a</surname>
<given-names>V&#xed;ctor Hugo</given-names>
</name>
<xref ref-type="aff" rid="aff18">
<sup>18</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Lara-Ramos</surname>
<given-names>Jos&#xe9; Ram&#xf3;n</given-names>
</name>
<xref ref-type="aff" rid="aff18">
<sup>18</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/1481157"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Gonz&#xe1;lez-Ulivarri</surname>
<given-names>Juana Esther</given-names>
</name>
<xref ref-type="aff" rid="aff19">
<sup>19</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Mart&#xed;nez-Silva</surname>
<given-names>Sof&#xed;a Irene</given-names>
</name>
<xref ref-type="aff" rid="aff20">
<sup>20</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Espinoza-Anrubio</surname>
<given-names>Gilberto</given-names>
</name>
<xref ref-type="aff" rid="aff21">
<sup>21</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Almeida-Hern&#xe1;ndez</surname>
<given-names>Carolina</given-names>
</name>
<xref ref-type="aff" rid="aff22">
<sup>22</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Ram&#xed;rez-Colorado</surname>
<given-names>Rosario</given-names>
</name>
<xref ref-type="aff" rid="aff23">
<sup>23</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Hern&#xe1;ndez-Mora</surname>
<given-names>Luis</given-names>
</name>
<xref ref-type="aff" rid="aff24">
<sup>24</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Garc&#xed;a-L&#xf3;pez</surname>
<given-names>Luis Ramiro</given-names>
</name>
<xref ref-type="aff" rid="aff25">
<sup>25</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Cruz-Ojeda</surname>
<given-names>Gabriela Adriana</given-names>
</name>
<xref ref-type="aff" rid="aff26">
<sup>26</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Godoy-Esquivel</surname>
<given-names>Arturo Emilio</given-names>
</name>
<xref ref-type="aff" rid="aff27">
<sup>27</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Contreras-Hern&#xe1;ndez</surname>
<given-names>Iris</given-names>
</name>
<xref ref-type="aff" rid="aff28">
<sup>28</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Medina-Hern&#xe1;ndez</surname>
<given-names>Abraham</given-names>
</name>
<xref ref-type="aff" rid="aff29">
<sup>29</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>L&#xf3;pez-Caballero</surname>
<given-names>Mar&#xed;a Guadalupe</given-names>
</name>
<xref ref-type="aff" rid="aff30">
<sup>30</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Hern&#xe1;ndez-Pineda</surname>
<given-names>Norma Ang&#xe9;lica</given-names>
</name>
<xref ref-type="aff" rid="aff31">
<sup>31</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Granados-Kraulles</surname>
<given-names>Jorge</given-names>
</name>
<xref ref-type="aff" rid="aff31">
<sup>31</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Rodr&#xed;guez-V&#xe1;zquez</surname>
<given-names>Mar&#xed;a Adriana</given-names>
</name>
<xref ref-type="aff" rid="aff32">
<sup>32</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Torres-Valle</surname>
<given-names>Delfino</given-names>
</name>
<xref ref-type="aff" rid="aff33">
<sup>33</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Cort&#xe9;s-Reyes</surname>
<given-names>Carlos</given-names>
</name>
<xref ref-type="aff" rid="aff34">
<sup>34</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/1003798"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Medrano-L&#xf3;pez</surname>
<given-names>Francisco</given-names>
</name>
<xref ref-type="aff" rid="aff35">
<sup>35</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>P&#xe9;rez-G&#xf3;mez</surname>
<given-names>Jessica Arleet</given-names>
</name>
<xref ref-type="aff" rid="aff35">
<sup>35</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Mart&#xed;nez-R&#xed;os</surname>
<given-names>Annel</given-names>
</name>
<xref ref-type="aff" rid="aff36">
<sup>36</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Aguilar-De-los-Santos</surname>
<given-names>Antonio</given-names>
</name>
<xref ref-type="aff" rid="aff37">
<sup>37</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Serafin-D&#xed;az</surname>
<given-names>Berenice</given-names>
</name>
<xref ref-type="aff" rid="aff38">
<sup>38</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Guti&#xe9;rrez-Rivera</surname>
<given-names>Mar&#xed;a de Lourdes</given-names>
</name>
<xref ref-type="aff" rid="aff39">
<sup>39</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/1480059"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Merino-Pasaye</surname>
<given-names>Laura Elizabeth</given-names>
</name>
<xref ref-type="aff" rid="aff20">
<sup>20</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Vargas-Alarc&#xf3;n</surname>
<given-names>Gilberto</given-names>
</name>
<xref ref-type="aff" rid="aff40">
<sup>40</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/104064"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Mata-Rocha</surname>
<given-names>Minerva</given-names>
</name>
<xref ref-type="aff" rid="aff41">
<sup>41</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/635440"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Sep&#xfa;lveda-Robles</surname>
<given-names>Omar Alejandro</given-names>
</name>
<xref ref-type="aff" rid="aff41">
<sup>41</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/939080"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Rosas-Vargas</surname>
<given-names>Hayde&#xe9;</given-names>
</name>
<xref ref-type="aff" rid="aff41">
<sup>41</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/1076385"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Hidalgo-Miranda</surname>
<given-names>Alfredo</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/53581"/>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Mej&#xed;a-Arangur&#xe9;</surname>
<given-names>Juan Manuel</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="aff41">
<sup>41</sup>
</xref>
<xref ref-type="aff" rid="aff42">
<sup>42</sup>
</xref>
<xref ref-type="author-notes" rid="fn001">
<sup>*</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/758647"/>
</contrib>
</contrib-group>
<aff id="aff1">
<sup>1</sup>
<institution>Laboratorio de Gen&#xf3;mica del C&#xe1;ncer, Instituto Nacional de Medicina Gen&#xf3;mica</institution>, <addr-line>Mexico City</addr-line>, <country>Mexico</country>
</aff>
<aff id="aff2">
<sup>2</sup>
<institution>Unidad de Investigaci&#xf3;n M&#xe9;dica en Epidemiolog&#xed;a Cl&#xed;nica, Unidad Medica de Alta Especialidad (UMAE) Hospital de Pediatr&#xed;a &#x201c;Dr. Silvestre Frenk Freund&#x201d;, Centro M&#xe9;dico Nacional &#x201c;Siglo XXI&#x201d;, Instituto Mexicano del Seguro Social (IMSS)</institution>, <addr-line>Mexico City</addr-line>, <country>Mexico</country>
</aff>
<aff id="aff3">
<sup>3</sup>
<institution>Unidad de Investigaci&#xf3;n M&#xe9;dica en Inmunolog&#xed;a e Infectolog&#xed;a, Hospital de Infectolog&#xed;a &#x201c;Dr. Daniel M&#xe9;ndez Hern&#xe1;ndez&#x201d;, &#x201c;La Raza&#x201d;, IMSS</institution>, <addr-line>Mexico City</addr-line>, <country>Mexico</country>
</aff>
<aff id="aff4">
<sup>4</sup>
<institution>Servicio de Hematolog&#xed;a Pedi&#xe1;trica, Hospital General &#x201c;Gaudencio Gonz&#xe1;lez Garza&#x201d;, Centro M&#xe9;dico Nacional &#x201c;La Raza&#x201d;, IMSS</institution>, <addr-line>Mexico City</addr-line>, <country>Mexico</country>
</aff>
<aff id="aff5">
<sup>5</sup>
<institution>Departamento de Hemato-Oncolog&#xed;a, Hospital Infantil de M&#xe9;xico Federico G&#xf3;mez</institution>, <addr-line>Mexico City</addr-line>, <country>Mexico</country>
</aff>
<aff id="aff6">
<sup>6</sup>
<institution>Servicio de Hematolog&#xed;a, Departamento de Investigaci&#xf3;n, Hospital General de M&#xe9;xico Dr. Eduardo Liceaga</institution>, <addr-line>Mexico City</addr-line>, <country>Mexico</country>
</aff>
<aff id="aff7">
<sup>7</sup>
<institution>Departamento de Endocrinolog&#xed;a, Instituto Nacional de Cardiolog&#xed;a, Ignacio Ch&#xe1;vez</institution>, <addr-line>M&#xe9;xico City</addr-line>, <country>Mexico</country>
</aff>
<aff id="aff8">
<sup>8</sup>
<institution>Servicio de Hematolog&#xed;a Pedi&#xe1;trica Unidad Medica de Alta Especialidad (UMAE) Hospital de Pediatr&#xed;a &#x201c;Dr. Silvestre Frenk Freund&#x201d;, Centro M&#xe9;dico Nacional &#x201c;Siglo XXI&#x201d;, IMSS</institution>, <addr-line>Mexico City</addr-line>, <country>Mexico</country>
</aff>
<aff id="aff9">
<sup>9</sup>
<institution>Servicio de Cirug&#xed;a Pedi&#xe1;trica, Hospital General &#x201c;Gaudencio Gonz&#xe1;lez Garza&#x201d;, Centro M&#xe9;dico Nacional (CMN) &#x201c;La Raza&#x201d;, IMSS</institution>, <addr-line>Mexico City</addr-line>, <country>Mexico</country>
</aff>
<aff id="aff10">
<sup>10</sup>
<institution>Servicio de Hematolog&#xed;a Pedi&#xe1;trica, Hospital General Regional &#x201c;Carlos McGregor S&#xe1;nchez Navarro&#x201d;, IMSS</institution>, <addr-line>Mexico City</addr-line>, <country>Mexico</country>
</aff>
<aff id="aff11">
<sup>11</sup>
<institution>Cirug&#xed;a Pedi&#xe1;trica, Hospital Regional &#x201c;General Ignacio Zaragoza&#x201d;, Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado (ISSSTE)</institution>, <addr-line>Mexico City</addr-line>, <country>Mexico</country>
</aff>
<aff id="aff12">
<sup>12</sup>
<institution>Servicio de Onco-Pediatria, Hospital Ju&#xe1;rez de M&#xe9;xico</institution>, <addr-line>Mexico City</addr-line>, <country>Mexico</country>
</aff>
<aff id="aff13">
<sup>13</sup>
<institution>Servicio de Oncolog&#xed;a, Hospital Pedi&#xe1;trico de Moctezuma, Secretar&#xed;a de Salud de la Ciudad de M&#xe9;xico (SSCDMX)</institution>, <addr-line>Mexico City</addr-line>, <country>Mexico</country>
</aff>
<aff id="aff14">
<sup>14</sup>
<institution>Servicio de Pediatr&#xed;a, Hospital General de Tl&#xe1;huac</institution>, <addr-line>Mexico City</addr-line>, <country>Mexico</country>
</aff>
<aff id="aff15">
<sup>15</sup>
<institution>Servicio de Hematolog&#xed;a Pedi&#xe1;trica, Hospital General de M&#xe9;xico</institution>, <addr-line>Mexico City</addr-line>, <country>Mexico</country>
</aff>
<aff id="aff16">
<sup>16</sup>
<institution>Coordinaci&#xf3;n Cl&#xed;nica y Servicio de Cirug&#xed;a Pedi&#xe1;trica, Hospital General Regional (HGR) No. 1 &#x201c;Dr. Carlos Mac Gregor S&#xe1;nchez Navarro&#x201d;, IMSS</institution>, <addr-line>Mexico City</addr-line>, <country>Mexico</country>
</aff>
<aff id="aff17">
<sup>17</sup>
<institution>Servicio de Hematolog&#xed;a Pedi&#xe1;trica, Centro M&#xe9;dico Nacional &#x201c;20 de Noviembre&#x201d;, ISSSTE</institution>, <addr-line>Mexico City</addr-line>, <country>Mexico</country>
</aff>
<aff id="aff18">
<sup>18</sup>
<institution>Servicio de Hemato-Oncolog&#xed;a Hospital Infantil de Tamaulipas</institution>, <addr-line>Cd. Victoria</addr-line>, <country>Mexico</country>
</aff>
<aff id="aff19">
<sup>19</sup>
<institution>Jefatura de Ense&#xf1;anza, Hospital Pedi&#xe1;trico de Iztacalco, SSCDMX</institution>, <addr-line>Mexico City</addr-line>, <country>Mexico</country>
</aff>
<aff id="aff20">
<sup>20</sup>
<institution>Jefatura de Ense&#xf1;anza, Hospital Pedi&#xe1;trico de Iztapalapa, SSCDMX</institution>, <addr-line>Mexico City</addr-line>, <country>Mexico</country>
</aff>
<aff id="aff21">
<sup>21</sup>
<institution>Servicio de Pediatr&#xed;a, Hospital General Zona (HGZ) No. 8 &#x201c;Dr. Gilberto Flores Izquierdo&#x201d; IMSS</institution>, <addr-line>Mexico City</addr-line>, <country>Mexico</country>
</aff>
<aff id="aff22">
<sup>22</sup>
<institution>Jefatura de Ense&#xf1;anza, Hospital General de Ecatepec &#x201c;Las Am&#xe9;ricas&#x201d;, Instituto de Salud del Estado de M&#xe9;xico (ISEM)</institution>, <addr-line>Mexico City</addr-line>, <country>Mexico</country>
</aff>
<aff id="aff23">
<sup>23</sup>
<institution>Jefatura de Ense&#xf1;anza, Hospital Pedi&#xe1;trico La Villa, SSCDMX</institution>, <addr-line>Mexico City</addr-line>, <country>Mexico</country>
</aff>
<aff id="aff24">
<sup>24</sup>
<institution>Jefatura de Ense&#xf1;anza, Hospital Pedi&#xe1;trico San Juan de Arag&#xf3;n, Secretar&#xed;a de Salud (SS)</institution>, <addr-line>Mexico City</addr-line>, <country>Mexico</country>
</aff>
<aff id="aff25">
<sup>25</sup>
<institution>Servicio de Pediatr&#xed;a, Hospital Pedi&#xe1;trico de Tacubaya, SSCDMX</institution>, <addr-line>Mexico City</addr-line>, <country>Mexico</country>
</aff>
<aff id="aff26">
<sup>26</sup>
<institution>Coordinaci&#xf3;n Cl&#xed;nica de Educaci&#xf3;n e Investigaci&#xf3;n en Salud, HGZ No. 47, IMSS</institution>, <addr-line>Mexico City</addr-line>, <country>Mexico</country>
</aff>
<aff id="aff27">
<sup>27</sup>
<institution>Servicio de Cirug&#xed;a Pedi&#xe1;trica, Hospital Pedi&#xe1;trico de Moctezuma, SSCDMX</institution>, <addr-line>Mexico City</addr-line>, <country>Mexico</country>
</aff>
<aff id="aff28">
<sup>28</sup>
<institution>Coordinaci&#xf3;n de Investigaci&#xf3;n en Salud, IMSS</institution>, <addr-line>Mexico City</addr-line>, <country>Mexico</country>
</aff>
<aff id="aff29">
<sup>29</sup>
<institution>Pediatr&#xed;a, Hospital Materno-Pedi&#xe1;trico de Xochimilco, SSCDMX</institution>, <addr-line>Mexico City</addr-line>, <country>Mexico</country>
</aff>
<aff id="aff30">
<sup>30</sup>
<institution>Jefatura de Ense&#xf1;anza, Hospital Pedi&#xe1;trico de Coyoac&#xe1;n, SSCDMX</institution>, <addr-line>Mexico City</addr-line>, <country>Mexico</country>
</aff>
<aff id="aff31">
<sup>31</sup>
<institution>Coordinaci&#xf3;n Cl&#xed;nica y Pediatr&#xed;a del Hospital General de Zona 76, IMSS</institution>, <addr-line>Mexico City</addr-line>, <country>Mexico</country>
</aff>
<aff id="aff32">
<sup>32</sup>
<institution>Coordinaci&#xf3;n Cl&#xed;nica y Pediatr&#xed;a del Hospital General de Zona 68, IMSS</institution>, <addr-line>Mexico City</addr-line>, <country>Mexico</country>
</aff>
<aff id="aff33">
<sup>33</sup>
<institution>Coordinaci&#xf3;n Cl&#xed;nica y Pediatr&#xed;a del Hospital General de Zona 71, IMSS</institution>, <addr-line>Mexico City</addr-line>, <country>Mexico</country>
</aff>
<aff id="aff34">
<sup>34</sup>
<institution>Pediatr&#xed;a, Hospital General Dr. Dar&#xed;o Fern&#xe1;ndez Fierro, ISSSTE</institution>, <addr-line>Mexico City</addr-line>, <country>Mexico</country>
</aff>
<aff id="aff35">
<sup>35</sup>
<institution>Coordinaci&#xf3;n Cl&#xed;nica y Servicio de Pediatr&#xed;a, HGR No. 72 &#x201c;Dr. Vicente Santos Guajardo&#x201d;, IMSS</institution>, <addr-line>Mexico City</addr-line>, <country>Mexico</country>
</aff>
<aff id="aff36">
<sup>36</sup>
<institution>Cirug&#xed;a Pedi&#xe1;trica del Hospital Regional &#x201c;General Ignacio Zaragoza&#x201d;, ISSSTE</institution>, <addr-line>Mexico City</addr-line>, <country>Mexico</country>
</aff>
<aff id="aff37">
<sup>37</sup>
<institution>Coordinaci&#xf3;n Cl&#xed;nica y Pediatr&#xed;a del Hospital General de Zona 98, IMSS</institution>, <addr-line>Mexico City</addr-line>, <country>Mexico</country>
</aff>
<aff id="aff38">
<sup>38</sup>
<institution>Coordinaci&#xf3;n Cl&#xed;nica y Pediatr&#xed;a del Hospital General de Zona 57, IMSS</institution>, <addr-line>Mexico City</addr-line>, <country>Mexico</country>
</aff>
<aff id="aff39">
<sup>39</sup>
<institution>Servicio de Oncolog&#xed;a Pedi&#xe1;trica  Unidad Medica de Alta Especialidad (UMAE) Hospital de Pediatr&#xed;a &#x201c;Dr. Silvestre Frenk Freund&#x201d;, IMSS</institution>, <addr-line>Mexico City</addr-line>, <country>Mexico</country>
</aff>
<aff id="aff40">
<sup>40</sup>
<institution>Departamento of Biolog&#xed;a Molecular, Instituto Nacional de Cardiolog&#xed;a Ignacio Ch&#xe1;vez</institution>, <addr-line>Mexico City</addr-line>, <country>Mexico</country>
</aff>
<aff id="aff41">
<sup>41</sup>
<institution>Unidad de Investigaci&#xf3;n M&#xe9;dica en Gen&#xe9;tica Humana, Unidad Medica de Alta Especialidad (UMAE) Hospital de Pediatr&#xed;a &#x201c;Dr. Silvestre Frenk Freund&#x201d;, Centro M&#xe9;dico Nacional &#x201c;Siglo XXI&#x201d;, IMSS</institution>, <addr-line>Mexico City</addr-line>, <country>Mexico</country>
</aff>
<aff id="aff42">
<sup>42</sup>
<institution>Facultad de Medicina, Universidad Nacional Aut&#xf3;noma de M&#xe9;xico</institution>, <addr-line>Mexico City</addr-line>, <country>Mexico</country>
</aff>
<author-notes>
<fn fn-type="edited-by">
<p>Edited by: Yong-Mi Kim, Children&#x2019;s Hospital of Los Angeles, United States</p>
</fn>
<fn fn-type="edited-by">
<p>Reviewed by: Danuta Januszkiewicz-Lewandowska, Poznan University of Medical Sciences, Poland; Adel Abaskharon Guirgis, University of Sadat City, Egypt</p>
</fn>
<fn fn-type="corresp" id="fn001">
<p>*Correspondence: Silvia Jim&#xe9;nez-Morales, <email xlink:href="mailto:sjimenez@inmegen.gob.mx">sjimenez@inmegen.gob.mx</email>; Juan Manuel Mej&#xed;a-Arangur&#xe9;, <email xlink:href="mailto:jmejia@inmegen.gob.mx">jmejia@inmegen.gob.mx</email>
</p>
</fn>
<fn fn-type="other" id="fn002">
<p>This article was submitted to Pediatric Oncology, a section of the journal Frontiers in Oncology</p>
</fn>
</author-notes>
<pub-date pub-type="epub">
<day>05</day>
<month>11</month>
<year>2021</year>
</pub-date>
<pub-date pub-type="collection">
<year>2021</year>
</pub-date>
<volume>11</volume>
<elocation-id>762063</elocation-id>
<history>
<date date-type="received">
<day>20</day>
<month>08</month>
<year>2021</year>
</date>
<date date-type="accepted">
<day>12</day>
<month>10</month>
<year>2021</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright &#xa9; 2021 Jim&#xe9;nez-Morales, N&#xfa;&#xf1;ez-Enr&#xed;quez, Cruz-Islas, Bekker-M&#xe9;ndez, Jim&#xe9;nez-Hern&#xe1;ndez, Medina-Sanson, Olarte-Carrillo, Mart&#xed;nez-Tovar, Flores-Lujano, Ram&#xed;rez-Bello, P&#xe9;rez-Sald&#xed;var, Mart&#xed;n-Trejo, P&#xe9;rez-Lorenzana, Amador-S&#xe1;nchez, Mora-R&#xed;os, Pe&#xf1;aloza-Gonz&#xe1;lez, Duarte-Rodr&#xed;guez, Torres-Nava, Flores-Bautista, Espinosa-Elizondo, Rom&#xe1;n-Zepeda, Flores-Villegas, Tamez-G&#xf3;mez, L&#xf3;pez-Garc&#xed;a, Lara-Ramos, Gonz&#xe1;lez-Ulivarri, Mart&#xed;nez-Silva, Espinoza-Anrubio, Almeida-Hern&#xe1;ndez, Ram&#xed;rez-Colorado, Hern&#xe1;ndez-Mora, Garc&#xed;a-L&#xf3;pez, Cruz-Ojeda, Godoy-Esquivel, Contreras-Hern&#xe1;ndez, Medina-Hern&#xe1;ndez, L&#xf3;pez-Caballero, Hern&#xe1;ndez-Pineda, Granados-Kraulles, Rodr&#xed;guez-V&#xe1;zquez, Torres-Valle, Cort&#xe9;s-Reyes, Medrano-L&#xf3;pez, P&#xe9;rez-G&#xf3;mez, Mart&#xed;nez-R&#xed;os, Aguilar-De-los-Santos, Serafin-D&#xed;az, Guti&#xe9;rrez-Rivera, Merino-Pasaye, Vargas-Alarc&#xf3;n, Mata-Rocha, Sep&#xfa;lveda-Robles, Rosas-Vargas, Hidalgo-Miranda and Mej&#xed;a-Arangur&#xe9;</copyright-statement>
<copyright-year>2021</copyright-year>    <copyright-holder>Jim&#xe9;nez-Morales, N&#xfa;&#xf1;ez-Enr&#xed;quez, Cruz-Islas, Bekker-M&#xe9;ndez, Jim&#xe9;nez-Hern&#xe1;ndez, Medina-Sanson, Olarte-Carrillo, Mart&#xed;nez-Tovar, Flores-Lujano, Ram&#xed;rez-Bello, P&#xe9;rez-Sald&#xed;var, Mart&#xed;n-Trejo, P&#xe9;rez-Lorenzana, Amador-S&#xe1;nchez, Mora-R&#xed;os, Pe&#xf1;aloza-Gonz&#xe1;lez, Duarte-Rodr&#xed;guez, Torres-Nava, Flores-Bautista, Espinosa-Elizondo, Rom&#xe1;n-Zepeda, Flores-Villegas, Tamez-G&#xf3;mez, L&#xf3;pez-Garc&#xed;a, Lara-Ramos, Gonz&#xe1;lez-Ulivarri, Mart&#xed;nez-Silva, Espinoza-Anrubio, Almeida-Hern&#xe1;ndez, Ram&#xed;rez-Colorado, Hern&#xe1;ndez-Mora, Garc&#xed;a-L&#xf3;pez, Cruz-Ojeda, Godoy-Esquivel, Contreras-Hern&#xe1;ndez, Medina-Hern&#xe1;ndez, L&#xf3;pez-Caballero, Hern&#xe1;ndez-Pineda, Granados-Kraulles, Rodr&#xed;guez-V&#xe1;zquez, Torres-Valle, Cort&#xe9;s-Reyes, Medrano-L&#xf3;pez, P&#xe9;rez-G&#xf3;mez, Mart&#xed;nez-R&#xed;os, Aguilar-De-los-Santos, Serafin-D&#xed;az, Guti&#xe9;rrez-Rivera, Merino-Pasaye, Vargas-Alarc&#xf3;n, Mata-Rocha, Sep&#xfa;lveda-Robles, Rosas-Vargas, Hidalgo-Miranda and Mej&#xed;a-Arangur&#xe9;</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/">
<p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</p>
</license>
</permissions>
<abstract>
<sec>
<title>Background</title>
<p>Acute lymphoblastic leukemia (ALL) is characterized by an abnormal proliferation of immature lymphocytes, in whose development involves both environmental and genetic factors. It is well known that single nucleotide polymorphisms (SNPs) in coding and noncoding genes contribute to the susceptibility to ALL. This study aims to determine whether SNPs in <italic>miR-146a</italic>, <italic>miR-196a-2</italic>, <italic>miR-499a</italic>, and <italic>miR-612</italic> genes are associated with the risk to ALL in pediatric Mexican population.</p>
</sec>
<sec>
<title>Methods</title>
<p>A multicenter case-control study was carried out including patients with <italic>de novo</italic> diagnosis of ALL and healthy subjects as control group. The DNA samples were obtained from saliva and peripheral blood, and the genotyping of rs2910164, rs12803915, rs11614913, and rs3746444 was performed using the 5&#x2032;exonuclease technique. Gene-gene interaction was evaluated by the multifactor dimensionality reduction (MDR) software.</p>
</sec>
<sec>
<title>Results</title>
<p>
<italic>miR-499a</italic> rs3746444 showed significant differences among cases and controls. The rs3746444G allele was found as a risk factor to ALL (OR, 1.6 [95% CI, 1.05&#x2013;2.5]; <italic>p</italic> = 0.028). The homozygous GG genotype of rs3746444 confers higher risk to ALL than the AA genotype (OR, 5.3 [95% CI, 1.23&#x2013;23.4]; <italic>p</italic> = 0.01). Moreover, GG genotype highly increases the risk to ALL in male group (OR, 17.6 [95% CI, 1.04&#x2013;298.9]; <italic>p</italic> = 0.00393). In addition, an association in a gender-dependent manner among SNPs located in <italic>miR-146a</italic> and <italic>miR-196a-2</italic> genes and ALL susceptibility was found.</p>
</sec>
<sec>
<title>Conclusion</title>
<p>Our findings suggest that SNP located in <italic>miR-499a</italic>, <italic>miR-146a</italic>, and <italic>miR-196a-2</italic> genes confer risk to ALL in Mexican children. Experimental analysis to decipher the role of these SNPs in human hematopoiesis could improve our understanding of the molecular mechanism underlying the development of ALL.</p>
</sec>
</abstract>
<kwd-group>
<kwd>acute lymphoblastic leukemia</kwd>
<kwd>
<italic>mir-146a</italic>
</kwd>
<kwd>
<italic>mir-196a-2</italic>
</kwd>
<kwd>
<italic>miR-499a</italic>
</kwd>
<kwd>
<italic>miR-612</italic>
</kwd>
<kwd>association study</kwd>
<kwd>Mexican population</kwd>
<kwd>single nucleotide polymorphism</kwd>
</kwd-group>
<counts>
<fig-count count="1"/>
<table-count count="3"/>
<equation-count count="0"/>
<ref-count count="51"/>
<page-count count="10"/>
<word-count count="4715"/>
</counts>
</article-meta>
</front>
<body>
<sec id="s1" sec-type="intro">
<title>Introduction</title>
<p>Acute lymphoblastic leukemia (ALL) is the most common pediatric hematological malignancy around the world, representing over 80% of all cases under 18 years old (<xref ref-type="bibr" rid="B1">1</xref>). This entity is highly prevalent in Mexican population, which displays one of the highest rate of relapse and death in comparison with other ethnic groups even after using chemotherapeutic approaches implemented in developed countries (<xref ref-type="bibr" rid="B2">2</xref>, <xref ref-type="bibr" rid="B3">3</xref>). ALL emerges by an abnormal proliferation of immature lymphocytes and their progenitors that replace the hematopoietic elements in the bone marrow and other lymphoid organs. So far, most of the causes of ALL are undeciphered; however, it is well known that an interaction within environmental and genetic factors is needed to develop this malignancy (<xref ref-type="bibr" rid="B4">4</xref>&#x2013;<xref ref-type="bibr" rid="B6">6</xref>). Among the identified risk genetic factors to suffer ALL are the single nucleotide polymorphisms (SNP), both, in coding and no coding genes (<xref ref-type="bibr" rid="B6">6</xref>&#x2013;<xref ref-type="bibr" rid="B9">9</xref>). No coding genes comprises around 98% of the human-transcribed genome, which is mainly represented by microRNAs (miRNAs) and long noncoding RNAs (lncRNAs) that play a relevant role in LLA and other types of cancer (<xref ref-type="bibr" rid="B10">10</xref>). miRNAs are small endogenous RNAs of 19&#x2013;25 nucleotides that function as posttranscriptional regulators silencing specific mRNAs. miRNAs interact with their targeted mRNAs by complementary base pairing, most of them in the 3&#x2032;-untranslated region (UTR) of the target mRNA, although interplay in the 5&#x2032;UTR region has also been documented. Targeted coding mRNAs by specific miRNAs could be either in complete or incomplete fashion (<xref ref-type="bibr" rid="B11">11</xref>). Experimental evidences have revealed that miRNA dysfunction contributes to the establishment of diverse human diseases, since miRNA-mRNA-specific interaction makes fine-scale adjustments to protein outputs (<xref ref-type="bibr" rid="B8">8</xref>, <xref ref-type="bibr" rid="B12">12</xref>, <xref ref-type="bibr" rid="B13">13</xref>). It has been identified that several SNP located into miRNA gene sequences are closely responsive for their abnormal function by modifying pri-miRNA transcription, pri-miRNA/pre-miRNA processing, or by disrupting miRNA-mRNA interactions (<xref ref-type="bibr" rid="B14">14</xref>, <xref ref-type="bibr" rid="B15">15</xref>). The rs2910164 G/C in <italic>miR-146a</italic> gene has been reported as an alterer of the gene expression, then its targeted mRNAs, which are involved in fundamental biological processes (cell differentiation, hematopoyesis, and innate and adaptive immunity, etc.) (<xref ref-type="bibr" rid="B16">16</xref>, <xref ref-type="bibr" rid="B17">17</xref>). The rs2910164 has been associated with many types of cancer and several immune-mediated diseases (<xref ref-type="bibr" rid="B18">18</xref>&#x2013;<xref ref-type="bibr" rid="B20">20</xref>); however, its association with ALL has shown controversial results (<xref ref-type="bibr" rid="B9">9</xref>, <xref ref-type="bibr" rid="B17">17</xref>, <xref ref-type="bibr" rid="B21">21</xref>). Another functional miR-SNP is rs3746444, which results from an A-to-G substitution in the seed region of <italic>miR-499a</italic>, was reported as significantly associated with an increased susceptibility to several human conditions, including cancer (<xref ref-type="bibr" rid="B19">19</xref>, <xref ref-type="bibr" rid="B22">22</xref>). To know whether rs2910164 G/C in <italic>miR-146a</italic>, rs11614913 T/C in <italic>miR-196a-2</italic>, rs3746444 A/G in <italic>miR-499a</italic>, and rs12803915 G/A in <italic>miR-612</italic> are associated with ALL in Mexican children, we performed a case control study.</p>
</sec>
<sec id="s2">
<title>Material and Methods</title>
<sec id="s2_1">
<title>Subjects</title>
<p>As part of the Mexican Interinstitutional Group for the Identification of the Causes of Childhood Leukemia (MIGICCL), we conducted a case-controls study from August 1, 2014, to July 31, 2016. Participants were younger than 18 years, residents of the Metropolitan Area of Mexico City, and recruited from public hospitals and health institutions from Mexico City, Mexico as was described previously by Medina-Sanzon et&#xa0;al. (<xref ref-type="bibr" rid="B6">6</xref>). ALL diagnosis was established by either a hematologist or an oncologist according to clinical characteristics, and bone marrow (BM) aspirate data. Gender, age at diagnosis, white blood cell count (WBC), immunophenotype, and risk classification group were registered from the patients&#x2019; medical records. We used the National Cancer Institute (NCI) risk criteria for ALL case stratification as follows: (a) standard risk: 1&#x2013;9.99 years of age or WBC &lt;50 &#xd7; 10^9/L, and (b) high risk: &#x2264;1 or &#x2265;10 years of age and/or WBC &#x2265;50 &#xd7; 10^9/L. Patients included in the study were treated with chemotherapy, none of them received HSCT therapy. Relapse was considered when &#x2265;5% leukemic blasts were detected in BM sample during the first 36 months after having achieved complete remission (CR). Early mortality was defined as the patient&#x2019;s death during the first 24 months. Cases with Down syndrome were excluded from the analysis. All institutional committees of Ethics, Research, and Biosecurity of the participant institutions approved this study. Written informed consent was obtained from all participants and the children&#x2019;s parents. Patients &#x2265;8 years old gave their assent (when possible) to be included in the present study. Cases and controls were selected according to criteria described in a previous study (<xref ref-type="bibr" rid="B6">6</xref>). Briefly, controls were recruited from second-level hospitals of the same health institution that referred the children with ALL to the third-level care hospitals. Control children were recruited from the departments of ambulatory surgery, pediatrics, and ophthalmology; orthopedic outpatient clinics; and the emergency room of the referred hospitals and have no leukemia, hematological diseases, allergies, infections, and congenital malformations. A set of adult patients was included to test the associated SNP <italic>miR-499a_</italic> rs3746444. The group of adult patients and controls is described in the <italic>Material and Methods</italic> section in the <xref ref-type="supplementary-material" rid="SM1">
<bold>Supplementary Material</bold>
</xref>.</p>
</sec>
<sec id="s2_2">
<title>DNA Extraction, SNP Selection, and Genotyping</title>
<p>Genomic DNA from saliva or peripheral blood was obtained according to the ORAGENE Purification Kit (DNA Genotek Inc., Kanata, ON, Canada) and the Gentra Kit (Gentra Systems Inc., Minneapolis, MN, USA) according to the manufacturer&#x2019;s instructions. DNA purity and concentration were determined by sypectrofotometry (Nanodrop-1000). The rs2910164 (<italic>miR-146a</italic>), rs11614913 (<italic>miR-196a-2</italic>), rs3746444 (<italic>miR-499a</italic>), and rs12803915 (<italic>miR-612</italic>) were selected base on previous association studies in ALL and other malignancies (<xref ref-type="bibr" rid="B8">8</xref>, <xref ref-type="bibr" rid="B9">9</xref>, <xref ref-type="bibr" rid="B13">13</xref>, <xref ref-type="bibr" rid="B17">17</xref>, <xref ref-type="bibr" rid="B21">21</xref>, <xref ref-type="bibr" rid="B23">23</xref>&#x2013;<xref ref-type="bibr" rid="B26">26</xref>). Genotyping was performed using the 5&#x2032;exonuclease technique and TaqMan MGB chemistry in a QuantStudio 5 system according to the manufacturer&#x2019;s instructions (Thermo Fisher, Foster City, CA, USA). TaqMan probes used were C:15946974_10 (rs2910164), C:31185852_10 (rs11614913), C:_2142612_40 (rs3746444), and C:32062363_10 (rs12803915). PCR reaction contained 25 ng of genomic DNA, 2.5 &#xb5;l of TaqMan master mix, 0.0625 &#xb5;l of 40&#xd7; assay mix, and ddH<sub>2</sub>O up to a final volume of 5 &#xb5;l. The PCR protocol included denaturing at 95&#xb0;C for 10 min, followed by 40 cycles of denaturing at 95&#xb0;C for 15 s, and annealing and extension at 60&#xb0;C for 1 min. Genotypes were assigned automatically by measuring the allele-specific fluorescence by using QuantStudio Design and Analysis software 5 for allelic discrimination (Applied Biosystems, Foster City, CA, USA). The overall genotype call rate was over 98.0% and 100% concordance of a subset of randomly repeated samples during the genotyping.</p>
</sec>
<sec id="s2_3">
<title>Statistical Analyses</title>
<p>Hardy-Weinberg Equilibrium (HWE) test was performed using the FINETTI program (<uri xlink:href="http://ihg.gsf.de/cgicbin/hw/hwa1.pl">http://ihg.gsf.de/cgicbin/hw/hwa1.pl</uri>). Alleles and genotype frequencies were compared among groups by using Chi-square and Fisher&#x2019;s exact tests (when appropriate) implemented in the STATCALC program (Epi Info v.6.02 software, Centers for Disease Control and Prevention, Atlanta, GA). By comparing cases and controls, all SNPs were evaluated under the codominant, dominant, and recessive genetic models using the FINETTI program. Bonferroni correction test was applied. The multifactor dimensionality reduction (MDR) software (V 3.0.2) was used to evaluate gene-gene interactions (<xref ref-type="bibr" rid="B27">27</xref>). All <italic>p</italic>-values &#x2264; 0.05 were considered statistically significant.</p>
</sec>
</sec>
<sec id="s3" sec-type="results">
<title>Results</title>
<sec id="s3_1">
<title>Features of Studied Subjects</title>
<p>The present work included 678 subjects from Mexico City, of which, 423 were children with ALL, and 255 children non-ALL. The ALL children were followed up for at least 3 years (<xref ref-type="bibr" rid="B3">3</xref>&#x2013;<xref ref-type="bibr" rid="B7">7</xref>) after initial diagnosis. Males were more frequent than females either in cases (57.9% <italic>vs</italic>. 42.1%, respectively) nor controls (54.7% v/s 45.2%, respectively), but differences were not statistically significant (<italic>p</italic> = 0.43). The proportion of children under 10 years old were higher in both groups, and a significant difference was detected among cases (62.2%) and controls (71.1%) (<italic>p</italic> = 0.02). Median age of ALL children was 9.09 (0&#x2013;18) and 6.4 (0&#x2013;17) of the control group. Overall, 68.3% had &gt;90% blast in bone marrow; 91.2%, 6.9%, and 1.9% were pre-B, cell-T, and biphenotype, respectively. Available clinical data are shown in <xref ref-type="table" rid="T1">
<bold>Table&#xa0;1</bold>
</xref>.</p>
<table-wrap id="T1" position="float">
<label>Table&#xa0;1</label>
<caption>
<p>Clinical characteristics of patients with acute lymphoblastic leukemia.</p>
</caption>
<table frame="hsides">
<thead>
<tr>
<th valign="top" rowspan="2" align="left">Features</th>
<th valign="top" colspan="2" align="center">Cases (<italic>n</italic> = 423)</th>
</tr>
<tr>
<th valign="top" align="center">
<italic>n</italic>
</th>
<th valign="top" align="center">%</th>
</tr>
</thead>
<tbody>
<tr>
<td valign="top" colspan="3" align="left">
<bold>Gender</bold>
</td>
</tr>
<tr>
<td valign="top" align="left">&#x2003;Male</td>
<td valign="top" align="center">245</td>
<td valign="top" align="center">57.9</td>
</tr>
<tr>
<td valign="top" align="left">&#x2003;Female</td>
<td valign="top" align="center">178</td>
<td valign="top" align="center">42.1</td>
</tr>
<tr>
<td valign="top" colspan="3" align="left">
<bold>Age group (years)</bold>
</td>
</tr>
<tr>
<td valign="top" align="left">&#x2003;&lt;1</td>
<td valign="top" align="center">9</td>
<td valign="top" align="center">2.1</td>
</tr>
<tr>
<td valign="top" align="left">&#x2003;1&#x2013;9</td>
<td valign="top" align="center">258</td>
<td valign="top" align="center">61.0</td>
</tr>
<tr>
<td valign="top" align="left">&#x2003;&#x2265;10</td>
<td valign="top" align="center">156</td>
<td valign="top" align="center">36.9</td>
</tr>
<tr>
<td valign="top" colspan="3" align="left">
<bold>Age at diagnosis (years)</bold>
</td>
</tr>
<tr>
<td valign="top" align="left">&#x2003;Median (min&#x2013;max)</td>
<td valign="top" align="center">7.9 (0&#x2013;18)</td>
<td valign="top" align="center"/>
</tr>
<tr>
<td valign="top" colspan="3" align="left">
<bold>BM blast at diagnosis (%)</bold>
</td>
</tr>
<tr>
<td valign="top" align="left">&#x2003;&lt;90</td>
<td valign="top" align="center">135</td>
<td valign="top" align="center">31.7</td>
</tr>
<tr>
<td valign="top" align="left">&#x2003;&#x2265;90</td>
<td valign="top" align="center">288</td>
<td valign="top" align="center">68.3</td>
</tr>
<tr>
<td valign="top" align="left">&#x2003;Median (min&#x2013;max)</td>
<td valign="top" align="center">85.3 (20&#x2013;100)</td>
<td valign="top" align="center"/>
</tr>
<tr>
<td valign="top" colspan="3" align="left">
<bold>Inmunophenotype</bold>
</td>
</tr>
<tr>
<td valign="top" align="left">&#x2003;Pre-B Cell</td>
<td valign="top" align="center">386</td>
<td valign="top" align="center">91.2</td>
</tr>
<tr>
<td valign="top" align="left">&#x2003;Cell-T</td>
<td valign="top" align="center">29</td>
<td valign="top" align="center">6.9</td>
</tr>
<tr>
<td valign="top" align="left">&#x2003;Biphenotype</td>
<td valign="top" align="center">8</td>
<td valign="top" align="center">1.9</td>
</tr>
<tr>
<td valign="top" colspan="3" align="left">
<bold>NCI risk classification</bold>
</td>
</tr>
<tr>
<td valign="top" align="left">&#x2003;Standard risk</td>
<td valign="top" align="center">214</td>
<td valign="top" align="center">50.6</td>
</tr>
<tr>
<td valign="top" align="left">&#x2003;High risk</td>
<td valign="top" align="center">209</td>
<td valign="top" align="center">49.4</td>
</tr>
<tr>
<td valign="top" colspan="3" align="left">
<bold>Relapse</bold>
</td>
</tr>
<tr>
<td valign="top" align="left">&#x2003;No</td>
<td valign="top" align="center">346</td>
<td valign="top" align="center">81.8</td>
</tr>
<tr>
<td valign="top" align="left">&#x2003;Yes</td>
<td valign="top" align="center">77</td>
<td valign="top" align="center">18.2</td>
</tr>
<tr>
<td valign="top" colspan="3" align="left">
<bold>Relapse site</bold>
</td>
</tr>
<tr>
<td valign="top" align="left">&#x2003;Isolated BM</td>
<td valign="top" align="center">52</td>
<td valign="top" align="center">67.5</td>
</tr>
<tr>
<td valign="top" align="left">&#x2003;Isolated CNS</td>
<td valign="top" align="center">17</td>
<td valign="top" align="center">22.1</td>
</tr>
<tr>
<td valign="top" align="left">&#x2003;BM and CNS</td>
<td valign="top" align="center">2</td>
<td valign="top" align="center">2.6</td>
</tr>
<tr>
<td valign="top" align="left">&#x2003;BM and CNS and eye</td>
<td valign="top" align="center">1</td>
<td valign="top" align="center">1.3</td>
</tr>
<tr>
<td valign="top" align="left">&#x2003;CNS and eyes</td>
<td valign="top" align="center">1</td>
<td valign="top" align="center">1.3</td>
</tr>
<tr>
<td valign="top" align="left">&#x2003;BM and testis</td>
<td valign="top" align="center">3</td>
<td valign="top" align="center">3.9</td>
</tr>
<tr>
<td valign="top" align="left">&#x2003;Ovary</td>
<td valign="top" align="center">1</td>
<td valign="top" align="center">1.3</td>
</tr>
<tr>
<td valign="top" colspan="3" align="left">
<bold>Death</bold>
</td>
</tr>
<tr>
<td valign="top" align="left">&#x2003;No</td>
<td valign="top" align="center">364</td>
<td valign="top" align="center">86.0</td>
</tr>
<tr>
<td valign="top" align="left">&#x2003;Yes</td>
<td valign="top" align="center">59</td>
<td valign="top" align="center">14.0</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn>
<p>WBC, whole blood cell count; BM, bone marrow; NCI, National Cancer Institute; CNS, central nervous system.</p>
</fn>
</table-wrap-foot>
</table-wrap>
</sec>
<sec id="s3_2">
<title>Association Study</title>
<p>Except for <italic>miR-146a</italic>, the genotypes of <italic>miR-196a-2</italic>, <italic>miR-499a</italic>, and <italic>miR-612</italic> were in HWE in the control population. The association analysis between miRNA SNPs and ALL are described in <xref ref-type="table" rid="T2">
<bold>Table&#xa0;2</bold>
</xref> and <xref ref-type="supplementary-material" rid="SM1">
<bold>Supplementary Table S1</bold>
</xref>. Case-control analysis including all children showed a significant association among <italic>miR-499a</italic> rs374644 with ALL (<xref ref-type="table" rid="T2">
<bold>Table&#xa0;2</bold>
</xref>). <italic>miR-499a</italic> rs3746444G alelle observed an OR of 1.6 (95% CI, 1.008&#x2013;2.5), <italic>p</italic> = 0.028. However, this significance did not remain after Bonferroni correction test. To note, under codominant model analysis AA <italic>vs</italic>. GG, statistical significance was found: OR, 5.3 (95% CI, 1.23&#x2013;23.4); <italic>p</italic> = 0.01 (<xref ref-type="table" rid="T1">
<bold>Table&#xa0;1</bold>
</xref>). Stratification analysis by gender observed that <italic>miR-499a</italic> rs3746444G is associated with ALL in a gender-dependent manner, being a risk factor to males (OR, 2.46 [95% CI, 1.31&#x2013;4.60]; <italic>p</italic> = 0.0037) but no to girls (<italic>p</italic> = 0.95) (<xref ref-type="table" rid="T3">
<bold>Table&#xa0;3</bold>
</xref>). Moreover, in comparison with AA genotype, GG genotype highly increases the risk to ALL (OR, 17.6 [95% CI, 1.04&#x2013;298.9]; <italic>p</italic> = 0.00393) in males. Data are shown in <xref ref-type="table" rid="T3">
<bold>Table&#xa0;3</bold>
</xref>.</p>
<table-wrap id="T2" position="float">
<label>Table&#xa0;2</label>
<caption>
<p>Association analysis among miR-499 rs3746444 and acute lymphoblastic leukemia.</p>
</caption>
<table frame="hsides">
<thead>
<tr>
<th valign="top" rowspan="2" align="left"/>
<th valign="top" colspan="2" align="center">Children</th>
<th valign="top" rowspan="2" align="center">OR [CI], <italic>p</italic>-value</th>
<th valign="top" colspan="2" align="center">Adults</th>
<th valign="top" rowspan="2" align="center">OR [CI], <italic>p</italic>-value</th>
<th valign="top" colspan="2" align="center">All</th>
<th valign="top" rowspan="2" align="center">OR [CI], <italic>p</italic>-value</th>
</tr>
<tr>
<th valign="top" align="center">Control (%)</th>
<th valign="top" align="center">Cases <italic>n</italic> (%)</th>
<th valign="top" align="center">Control <italic>n</italic> (%)</th>
<th valign="top" align="center">Cases <italic>n</italic> (%)</th>
<th valign="top" align="center">Control <italic>n</italic> (%)</th>
<th valign="top" align="center">Cases <italic>n</italic> (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td valign="top" align="left">
<bold>
<italic>N</italic>
</bold>
</td>
<td valign="top" align="center">255</td>
<td valign="top" align="center">416</td>
<td valign="top" align="center"/>
<td valign="top" align="center">180</td>
<td valign="top" align="center">71</td>
<td valign="top" align="center"/>
<td valign="top" align="center">435</td>
<td valign="top" align="center">489</td>
<td valign="top" align="center"/>
</tr>
<tr>
<td valign="top" colspan="10" align="left">
<bold>Genotypes</bold>
</td>
</tr>
<tr>
<td valign="top" align="left"> AA</td>
<td valign="top" align="center">229 (89.8)</td>
<td valign="top" align="center">362 (87.0)</td>
<td valign="top" align="center"/>
<td valign="top" align="center">157 (87.2)</td>
<td valign="top" align="center">59 (83.1)</td>
<td valign="top" align="center"/>
<td valign="top" align="center">386 (88.7)</td>
<td valign="top" align="center">421 (86.1)</td>
<td valign="top" align="center"/>
</tr>
<tr>
<td valign="top" align="left"> AG</td>
<td valign="top" align="center">24 (9.4)</td>
<td valign="top" align="center">39 (9.3)</td>
<td valign="top" align="center"/>
<td valign="top" align="center">23 (12.8)</td>
<td valign="top" align="center">9 (12.7)</td>
<td valign="top" align="center"/>
<td valign="top" align="center">47 (10.8)</td>
<td valign="top" align="center">48 (9.8)</td>
<td valign="top" align="center"/>
</tr>
<tr>
<td valign="top" align="left"> GG</td>
<td valign="top" align="center">2 (0.8)</td>
<td valign="top" align="center">17 (4.8)</td>
<td valign="top" align="center"/>
<td valign="top" align="center">0 (0)</td>
<td valign="top" align="center">3 (4.2)</td>
<td valign="top" align="center"/>
<td valign="top" align="center">2 (0.5)</td>
<td valign="top" align="center">20 (4.1)</td>
<td valign="top" align="center"/>
</tr>
<tr>
<td valign="top" align="left">
<bold>Alelles</bold>
</td>
<td valign="top" align="center"/>
<td valign="top" align="center"/>
<td valign="top" align="center">1.6 [1.05&#x2013;2.5], 0.028<sup>*</sup>
</td>
<td valign="top" align="center"/>
<td valign="top" align="center"/>
<td valign="top" align="center">1.7 [0.87&#x2013;3.34], 0.11</td>
<td valign="top" align="center"/>
<td valign="top" align="center"/>
<td valign="top" align="center">1.58 [1.1&#x2013;2.2], 0.01<sup>*</sup>
</td>
</tr>
<tr>
<td valign="top" align="left"> A</td>
<td valign="top" align="center">482 (94.5)</td>
<td valign="top" align="center">763 (91.4)</td>
<td valign="top" align="center"/>
<td valign="top" align="center">337 (93.6)</td>
<td valign="top" align="center">127 (89.4)</td>
<td valign="top" align="center"/>
<td valign="top" align="center">819 (94.1)</td>
<td valign="top" align="center">824 (91.0)</td>
<td valign="top" align="center"/>
</tr>
<tr>
<td valign="top" align="left"> G</td>
<td valign="top" align="center">28 (5.5)</td>
<td valign="top" align="center">73 (8.8)</td>
<td valign="top" align="center"/>
<td valign="top" align="center">23 (6.4)</td>
<td valign="top" align="center">15 (10.6)</td>
<td valign="top" align="center"/>
<td valign="top" align="center">51 (5.9)</td>
<td valign="top" align="center">88 (9.0)</td>
<td valign="top" align="center"/>
</tr>
<tr>
<td valign="top" align="left">
<bold>Codominant</bold>
</td>
<td valign="top" align="center"/>
<td valign="top" align="center"/>
<td valign="top" align="center">5.3 [1.23&#x2013;23.4], 0.01<sup>*</sup>
</td>
<td valign="top" align="center"/>
<td valign="top" align="center"/>
<td valign="top" align="center">18.5 [0.94&#x2013;364], 0.005</td>
<td valign="top" align="center"/>
<td valign="top" align="center"/>
<td valign="top" align="center">9.16 [2.1&#x2013;39.4], 0.00033<sup>*</sup>
</td>
</tr>
<tr>
<td valign="top" align="left"> AA <italic>vs</italic>. GG</td>
<td valign="top" align="center"/>
<td valign="top" align="center"/>
<td valign="top" align="center"/>
<td valign="top" align="center"/>
<td valign="top" align="center"/>
<td valign="top" align="center"/>
<td valign="top" align="center"/>
<td valign="top" align="center"/>
<td valign="top" align="center"/>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn>
<p>OR, odds ratio; CI, confidence interval. <sup>*</sup>Statistically significant.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<table-wrap id="T3" position="float">
<label>Table&#xa0;3</label>
<caption>
<p>Association analysis among miR-499 rs3746444 and acute lymphoblastic leukemia in children stratified by gender.</p>
</caption>
<table frame="hsides">
<thead>
<tr>
<th valign="top" rowspan="2" align="left"/>
<th valign="top" colspan="2" align="center">Male</th>
<th valign="top" rowspan="2" align="center">OR [CI], <italic>p</italic>-value</th>
<th valign="top" colspan="2" align="center">Female</th>
<th valign="top" rowspan="2" align="center">OR [CI], <italic>p</italic>-value</th>
</tr>
<tr>
<th valign="top" align="center">Control (%)</th>
<th valign="top" align="center">Cases <italic>n</italic> (%)</th>
<th valign="top" align="center">Control <italic>n</italic> (%)</th>
<th valign="top" align="center">Cases <italic>n</italic> (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td valign="top" align="left">
<bold>
<italic>N</italic>
</bold>
</td>
<td valign="top" align="center">255</td>
<td valign="top" align="center">416</td>
<td valign="top" align="center"/>
<td valign="top" align="center">180</td>
<td valign="top" align="center">71</td>
<td valign="top" align="center"/>
</tr>
<tr>
<td valign="top" colspan="7" align="left">
<bold>Genotypes</bold>
</td>
</tr>
<tr>
<td valign="top" align="left"> AA</td>
<td valign="top" align="center">126 (89.8)</td>
<td valign="top" align="center">207 (87.0)</td>
<td valign="top" align="center"/>
<td valign="top" align="center">103 (87.2)</td>
<td valign="top" align="center">155 (83.1)</td>
<td valign="top" align="center"/>
</tr>
<tr>
<td valign="top" align="left"> AG</td>
<td valign="top" align="center">13 (9.4)</td>
<td valign="top" align="center">25 (9.3)</td>
<td valign="top" align="center"/>
<td valign="top" align="center">9 (12.8)</td>
<td valign="top" align="center">14 (12.7)</td>
<td valign="top" align="center"/>
</tr>
<tr>
<td valign="top" align="left"> GG</td>
<td valign="top" align="center">0 (0.8)</td>
<td valign="top" align="center">14 (4.8)</td>
<td valign="top" align="center"/>
<td valign="top" align="center">2 (0)</td>
<td valign="top" align="center">3 (4.2)</td>
<td valign="top" align="center"/>
</tr>
<tr>
<td valign="top" align="left">
<bold>Alelles</bold>
</td>
<td valign="top" align="center"/>
<td valign="top" align="center"/>
<td valign="top" align="center">2.46 [1.31&#x2013;4.60], 0.0037<sup>*</sup>
</td>
<td valign="top" align="center"/>
<td valign="top" align="center"/>
<td valign="top" align="center">1.021 [0.49&#x2013;2.09], 0.95</td>
</tr>
<tr>
<td valign="top" align="left"> A</td>
<td valign="top" align="center">482 (94.5)</td>
<td valign="top" align="center">763 (91.4)</td>
<td valign="top" align="center"/>
<td valign="top" align="center">337 (93.6)</td>
<td valign="top" align="center">127 (89.4)</td>
<td valign="top" align="center"/>
</tr>
<tr>
<td valign="top" align="left"> G</td>
<td valign="top" align="center">28 (5.5)</td>
<td valign="top" align="center">73 (8.8)</td>
<td valign="top" align="center"/>
<td valign="top" align="center">23 (6.4)</td>
<td valign="top" align="center">15 (10.6)</td>
<td valign="top" align="center"/>
</tr>
<tr>
<td valign="top" align="left">
<bold>Codominant</bold>
</td>
<td valign="top" align="center"/>
<td valign="top" align="center"/>
<td valign="top" align="center">17.6, [1.04&#x2013;298.9], 0.00393<sup>*</sup>
</td>
<td valign="top" align="center"/>
<td valign="top" align="center"/>
<td valign="top" align="center">0.99 [0.16 6.06], 0.99</td>
</tr>
<tr>
<td valign="top" align="left"> AA <italic>vs</italic>. GG</td>
<td valign="top" align="center"/>
<td valign="top" align="center"/>
<td valign="top" align="center"/>
<td valign="top" align="center"/>
<td valign="top" align="center"/>
<td valign="top" align="center"/>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn>
<p>OR, odds ratio; CI, confidence interval. <sup>*</sup>Statistically significant. Genotyping &gt;98%.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<p>
<italic>miR-146a</italic> rs2910164, <italic>miR-196a-2</italic> rs11614913, and <italic>miR-612</italic> rs12803915 association analysis including all children with ALL showed differences among cases and controls but were not statistically significant (<xref ref-type="supplementary-material" rid="SM1">
<bold>Supplementary Table S1</bold>
</xref>). The analysis stratified by gender revealed that homozygote genotype for the minor allele CC of <italic>miR-146a</italic> rs2910164 was differentially distributed among male ALL cases and male controls (OR, 4.3 (1.60&#x2013;11.61); <italic>p</italic> = 0.02). Meanwhile, <italic>miR-196a-2</italic> rs11619413 was associated with ALL in female (C <italic>vs</italic>. T: OR, 1.54 [95% CI, 1.08&#x2013;2.2]; <italic>p</italic> = 0.015) (<xref ref-type="supplementary-material" rid="SM1">
<bold>Supplementary Table S2</bold>
</xref>).</p>
</sec>
<sec id="s3_3">
<title>Association Between <italic>miR-146a</italic>, <italic>miR-196a-2</italic>, <italic>miR-499a</italic>, and <italic>miR-612</italic> SNPs With Clinical Characteristics</title>
<p>To know whether the studied SNPs were associated with clinical and biological ALL features, we performed the case-control analysis into the patients group stratified by gender, age group, immunophenotype, NCI-risk classification, relapse, death, and hereditary cancer family history (<xref ref-type="supplementary-material" rid="SM1">
<bold>Supplementary Table S3</bold>
</xref>). Significant differences among gender and age were found in the distribution of the <italic>miR-196a-2</italic> rs11614913C allele (<italic>p</italic> = 0.02, <italic>p</italic> = 0.02, respectively). Additionally, analysis comparing infants <italic>versus</italic> children older than 1 year was performed. <xref ref-type="supplementary-material" rid="SM1">
<bold>Supplementary Table S3</bold>
</xref> shows the results grouping the patients by age groups: &lt;1 year; 1&#x2013;9.9 and &#x2265;10 years, considering that it has been reported that adolescents with ALL also have a dismal prognosis in comparison with children below this age and is considered an important prognostic factor. Regarding immunophenotype, NCI risk classification, relapse, death, and hereditary family history, no significant differences were observed (<xref ref-type="supplementary-material" rid="SM1">
<bold>Supplementary Table S3</bold>
</xref>). Furthermore, we conducted survival analyses between the SNPs analyzed and the overall survival of pediatric patients with ALL, but no significant associations were observed neither including all cases nor after stratifying by child&#x2019;s sex and age groups.</p>
</sec>
<sec id="s3_4">
<title>Gene-Gene Interaction Analysis</title>
<p>To know whether <bold>g</bold>ene-gene interactions among <italic>miR-146a</italic>, <italic>miR-196a-2</italic>, <italic>miR-499</italic>a, and <italic>miR-612</italic> SNPs predict the risk to ALL, a MDR analysis was performed by including cases and controls having complete genotyping data of all evaluated SNPs. No SNP was identified as the best factor model. The multi<italic>locus</italic> model with maximum crossvalidation consistency (CVC) and minimum prediction error is displayed in <xref ref-type="supplementary-material" rid="SM1">
<bold>Supplementary Table S4</bold>
</xref>. Four-<italic>locus</italic> genotype combinations associated with the risk of ALL, as well as their distribution among cases (left) and controls (right) is summarizes in <xref ref-type="fig" rid="f1">
<bold>Figure&#xa0;1A</bold>
</xref>. This analysis gave evidence of epistasis or gene-gene interaction (<xref ref-type="fig" rid="f1">
<bold>Figures&#xa0;1B, C</bold>
</xref>). Entropy data showed that rs3746444 had the larger effect on the susceptibility to develop ALL (0.59%) followed by rs<italic>2910164</italic> (0.49%). Week synergy among <italic>miR-196a-2</italic> and <italic>miR-612</italic> was observed (orange line) (<xref ref-type="fig" rid="f1">
<bold>Figure&#xa0;1B</bold>
</xref>). Redundancy was observed among all SNPs (blue and green lines) (<xref ref-type="fig" rid="f1">
<bold>Figures&#xa0;1B, C</bold>
</xref>). To note, gene-gene gender interaction observed a strong synergy (red line) among <italic>miR-196a-2</italic> and gender (<xref ref-type="supplementary-material" rid="SM1">
<bold>Supplementary Figure S1</bold>
</xref>).</p>
<fig id="f1" position="float">
<label>Figure&#xa0;1</label>
<caption>
<p>Multifactor dimensionality reduction (MDR) analysis. <bold>(A)</bold> Four-<italic>locus</italic> MDR model. Genotype combinations with high risk (shaded dark grey) and low risk (shaded light grey) for acute lymphoblastic leukemia (ALL) and their distribution in cases (left bar) and controls (right bar). The patterns of high (shaded  and low-risk cells, which differ across each of the different multi locus dimension, means that the influence each genotype on the ALL risk  is dependent on the genotypes a each of the other three loci. <bold>(B)</bold> Interaction entropy graph for gene-gene interaction and ALL risk. Graph shows the percent of the entropy in case-control removed by each factor (boxes) and by each pair-wise combination of attributes (lines). Positive value and orange line indicate low degree of synergy and negative values and blue and green lines mean redundancy. Gold line means independency. <bold>(C)</bold> The dendrogram graphic shows the presence, strength, and nature of epistatic effects. The shorter the line connecting two attributes the stronger the interaction. Strength of interaction goes from left to right (gray line).</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fonc-11-762063-g001.tif"/>
</fig>
</sec>
</sec>
<sec id="s4" sec-type="discussion">
<title>Discussion</title>
<p>Mountain evidence reveals that miRNAs are relevant in the gene regulation contributing to the establishment of human diseases and modifying their treatment response of the patients. For instance, by using miRanda, TargetScan, and miRTarget2, it is predicted that <italic>AKT2</italic> is a potential target of <italic>miR-612</italic>, which has been reported as significantly upregulated in ALL patients. <italic>AKT2</italic> expression in lymphocytes correlates negatively with sensitive to glucocorticoids, and patients have poor prognosis (<xref ref-type="bibr" rid="B28">28</xref>&#x2013;<xref ref-type="bibr" rid="B30">30</xref>). For its part, <italic>miR-146a</italic> has been involved in megakaryopoiesis by activating innate immunity targets TIRAP and TRAF6 (<xref ref-type="bibr" rid="B31">31</xref>). In addition, experimental data have shown that SNPs in miRNAs could affect cell differentiation, proliferation, and apoptosis conducting cancer development. The SNPs rs2910164 in <italic>miR146a</italic>, rs11614913 in <italic>miR-196a-2</italic>, rs3746444 in <italic>miR-499</italic>a, and rs12803915 in <italic>miR-612</italic> are among the most studied SNPs in cancer. In a case-control study, we did no find association among rs12803915 of <italic>miR-612</italic> but to rs3746444 of <italic>miR-499a</italic> with ALL, as well as, in a gender-dependent manner rs2910164 of <italic>miR146a</italic>, and rs11614913 of <italic>miR-196a-2</italic> were associated with the risk to this disease.</p>
<p>To date, only three studies have explored the association among <italic>miR-499a</italic> rs3746444 and ALL. Our results are in line with the findings of de Souza et&#xa0;al., who studied 100 pediatric ALL patients, and 180 healthy individuals from Brazilian-amazon reported that <italic>miR499a</italic>_rs3746444 increases 17-fold the risk of development of ALL (<xref ref-type="bibr" rid="B26">26</xref>). We found that the mutant homozygote rs3746444GG genotype was associated with a 1.6-fold increase in the risk of developing ALL. However, our data are in contrast to those published previously by Gutierrez-Camino et&#xa0;al., who including 213 B-cell ALL pediatric patients and 387 controls from Spain, found a protective role of the G allele on the risk of ALL (<xref ref-type="bibr" rid="B8">8</xref>) and by Hasani et&#xa0;al., studying 75 children diagnosed with ALL and 115 children from Iran with no history of any type of cancer (<xref ref-type="bibr" rid="B23">23</xref>). To note, we explored whether <italic>miR-499a</italic> rs3746444 has in adults with ALL the same effect as we observed in children by genotyping 71 patients &gt;18 years old with clinical diagnosis of ALL and 180 healthy adults (1:1 female/male). Samples from ALL adults were obtained from the biobank of the Servicio de Hematolog&#xed;a, Hospital General de M&#xe9;xico. Adult control group was obtained from the DNA biobank of the laboratorio de Investigation, Hospital Ju&#xe1;rez de M&#xe9;xico. <italic>miR-499a</italic> rs3746444A allele frequency was very similar among children and adults (cases and controls) and notably, <italic>miR-499a</italic> rs3746444G allele was not detected in no-ALL adults (0%). However, differences among adult cases and adult controls or between children and adults were not statistically significant (<xref ref-type="table" rid="T2">
<bold>Table&#xa0;2</bold>
</xref>). Our study is the first to investigate the role of rs3746444 in the susceptibility to ALL in adults, which has been associated with common adulthood cancer types (<xref ref-type="bibr" rid="B22">22</xref>, <xref ref-type="bibr" rid="B32">32</xref>). The rs3746444 is located in pre-<italic>mir-499</italic> gene resulting changes of an A:U to a G:U pairing and mismatching that reduces the stability of the <italic>pre-miR-499</italic> secondary structure (<xref ref-type="bibr" rid="B33">33</xref>) and this SNP, located in the seed region of miR-499a could alter the targeted genes. In fact, Yang et&#xa0;al. (<xref ref-type="bibr" rid="B34">34</xref>) reported that this SNP potentially recognizes 573 new target genes and lost 5,392 original target genes. Several of these genes are involved in biological processes as cell proliferation and migration (<xref ref-type="bibr" rid="B35">35</xref>).</p>
<p>It is known that <italic>mir146a</italic> plays anti-inflammatory functions, has roles as tumor suppressor and commonly shows altered expression levels in human leukemia (<xref ref-type="bibr" rid="B32">32</xref>&#x2013;<xref ref-type="bibr" rid="B38">38</xref>). Data from ALL Jurkat cells have shown that <italic>miR-146</italic>a can promote growth of leukemia cells by regulating the expression anti-apoptosis factor Bcl-xL and altering the expression of diverse genes involved in T-cell differentiation (<xref ref-type="bibr" rid="B37">37</xref>&#x2013;<xref ref-type="bibr" rid="B39">39</xref>). Recent papers have given evidence that rs2910164 in <italic>miR146</italic> can modify the expression of nuclear factor (NF-&#x138;B) through reducing <italic>IRAK1</italic> and <italic>TRAF</italic> gene expression thus, driving inflammation and leukemia progression in myeloid cells (<xref ref-type="bibr" rid="B40">40</xref>). Stickel et&#xa0;al. (<xref ref-type="bibr" rid="B41">41</xref>) observed that patients with the <italic>miR-146a</italic> polymorphism rs2910164 display higher major histocompatibility complex class II (MHCII) molecule levels on monocytes. In addition, experimental evidences have shown that the rs2910164 in human allogeneic hematopoietic cell transplantation (allo-HCT) recipients significantly increases the risk for acute severe acute graft-<italic>versus</italic>-host disease in patients with hematological malignancies (<xref ref-type="bibr" rid="B41">41</xref>). The G to C polymorphism rs2910164 in <italic>miR146a</italic> changes the G:U pair to a C:U mismatch in the stem structure of <italic>miR-146a</italic> precursor, resulting in a reduced level of mature miR146a (<xref ref-type="bibr" rid="B36">36</xref>). To note, we found that <italic>miR-146a</italic> rs2910164 GG genotype confer risk to ALL in male. This SNP is widely associated with cancer, but association studies in ALL have reveled conflicting results. On one hand, it has been reported that <italic>miR-146a</italic> rs2910164 is associated with childhood ALL susceptibility in Asian population, including Iranian, Chinese, and Taiwanese (<xref ref-type="bibr" rid="B17">17</xref>, <xref ref-type="bibr" rid="B23">23</xref>, <xref ref-type="bibr" rid="B25">25</xref>). On the other hand, studies in Thailand, India, and China failed to replicate these results (<xref ref-type="bibr" rid="B9">9</xref>, <xref ref-type="bibr" rid="B21">21</xref>, <xref ref-type="bibr" rid="B42">42</xref>). No published study has reported an association among ALL and rs2910164 in a gene-dependent manner, and considering the higher prevalence of ALL in male than female, these findings should be deeply explored.</p>
<p>Regarding rs11614913 C/T, in the 3p mature miRNA region of <italic>miR-196a2</italic>, leads to a variation from G:T to G:C in the stem region of the <italic>miR-196a2</italic> precursor. Comparing the minimum free energy for optimal secondary structures of the SNP rs11614913 in pre-miR196a2 found that this SNP had no dramatic effect on its secondary structure (<xref ref-type="bibr" rid="B43">43</xref>); however, Hoffman et&#xa0;al. (<xref ref-type="bibr" rid="B44">44</xref>) already show that rs11614913C may affect the processing of pre-miRNA, modify both, its expression level and function, then alters its interactions with its targeted genes. In fact, various studies have observed a correlation among abnormal expression of <italic>miR-196a2</italic> and genes involved in cancer (<xref ref-type="bibr" rid="B45">45</xref>, <xref ref-type="bibr" rid="B46">46</xref>). Studies in several types of cancer suggest that the common rs11614913 variant may play a role in the development of malignancies in an ethnic-dependent manner (<xref ref-type="bibr" rid="B43">43</xref>, <xref ref-type="bibr" rid="B47">47</xref>, <xref ref-type="bibr" rid="B48">48</xref>). For instance, a meta-analysis including 41,673 cases and 49,570 controls from 111 studies revealed that <italic>mir-196a-2</italic> rs11614913 T allele was significantly associated with cancer risk only in Asians but not Caucasians (<xref ref-type="bibr" rid="B47">47</xref>). As for hematological malignancies, association data are scarce. Findings in Non-Hodgkin&#x2019;s lymphoma suggest that the <italic>miR-196a-2</italic> polymorphism may increase the risk of the disease by altering the expression of mature <italic>miR-196a</italic> (<xref ref-type="bibr" rid="B48">48</xref>). In ALL, two studies have published that rs11614913C allele contributes to an increased risk of this disease in Thailand, and China, but another one found no association results in Taiwanese ALL cases (<xref ref-type="bibr" rid="B13">13</xref>, <xref ref-type="bibr" rid="B24">24</xref>, <xref ref-type="bibr" rid="B49">49</xref>). Comparing the minimum free energy for optimal secondary structures of the SNP rs11614913 in <italic>pre-miR196a-2</italic> found no dramatic effect on its secondary structure (<xref ref-type="bibr" rid="B47">47</xref>). We found an association among this SNP with ALL risk in females, but whether this SNP is playing a role in ALL susceptibility remains unknown.</p>
<p>Regarding rs12803915 in <italic>mir-612</italic>, experimental studies reveal that rs12803915 SNP affects mature <italic>mir-612</italic> expression in a cell-type-specific manner. As example, Kim et&#xa0;al. observed that rs12803915A allele increases and decreases mature <italic>mir-612</italic> expression in prostate cancer and colon cancer cell lines, respectively (<xref ref-type="bibr" rid="B50">50</xref>). In ALL, two studies have explored this SNP (<xref ref-type="bibr" rid="B8">8</xref>, <xref ref-type="bibr" rid="B51">51</xref>). On one hand, the rs12803915 in <italic>mir-612</italic> was associated with ALL in patients from Spain (<xref ref-type="bibr" rid="B8">8</xref>). On the other hand, in 100 B-ALL cases and 105 controls from Iran, no association was observed (<xref ref-type="bibr" rid="B51">51</xref>).</p>
<p>To know whether there is a gene-gene interaction among the evaluated SNPs in the risk to ALL, we employed a MDR analysis. We observed that <italic>miR-499a</italic> is the main casual factor for ALL, a strong redundancy interaction effect of this SNP and <italic>miR-196a-2</italic> and <italic>miR-146a</italic> on ALL risk, and a low synergism with <italic>miR-612</italic>; thus, this analysis gave evidence of epistasis. Both genes have already been shown to be associated with cancer risk in various populations, but no data regarding their interaction has been published. To note, both SNPs have been found as susceptibility factors to ALL in a Spanish population (<xref ref-type="bibr" rid="B8">8</xref>).</p>
<p>The discrepancies on the association findings among the present work and other populations may be related to the sample selection, and the genetic background of the&#xa0;populations, since the linkage disequilibrium complex structure of the populations could mask the causal SNP (<xref ref-type="bibr" rid="B51">51</xref>). In addition, differences in the genetic background of cases and control could bias the association results. To note, our control group and a subset of the ALL cases belong to a genotyped cohort using 32 informative ancestry markers. As we published previously, ALL cases and controls are Mexican-Mestizo (<xref ref-type="bibr" rid="B6">6</xref>). However, to clarify the effect of miRNA polymorphism on ALL risk, studies including patients from different ethnicities and larger sample sizes are needed. Experimental analysis could also add data to decipher the role of <italic>miR-499</italic> in ALL.</p>
<p>In conclusion, our analysis revealed that <italic>miR-499</italic> rs3746444 confers risk to ALL and there is a gender-dependent association among <italic>miR-146a</italic> and <italic>miR-196a-2</italic> and ALL in Mexican children. Studies are needed to evaluate the potential molecular mechanisms underlying the contribution of these SNPs in ALL susceptibility.</p>
</sec>
<sec id="s5" sec-type="data-availability">
<title>Data Availability Statement</title>
<p>The original contributions presented in the study are included in the article/<xref ref-type="supplementary-material" rid="SM1">
<bold>Supplementary Material</bold>
</xref>. Further inquiries can be directed to the corresponding authors.</p>
</sec>
<sec id="s6" sec-type="ethics-statement">
<title>Ethics Statement</title>
<p>The studies involving human participants were reviewed and approved by the Ethics and National Committee of Scientific Research of the Instituto Mexicano del Seguro Social with number R-2013-785-062. Written informed consent to participate in this study was provided by the participants&#x2019; legal guardian/next of kin.</p>
</sec>
<sec id="s7" sec-type="author-contributions">
<title>Author Contributions</title>
<p>SJ-M: conceptualization. SJ-M, JN-E, JC-I, and JR-B: methodology. SJ-M, JN-E, JC-I, and JR-B: formal analysis. SJ-M: investigation. JN-E, VB-M, EJ-H, AM-S, IO-C, AM-T, JF-L, MP-S, JM-T, HP-L, RA-S, FM-R, JP-G, DD-R, JT-N, JF-B, RE-E, PR-Z, LF-V, ET-G, VL-G, JL-R, JG-U, SM-S, GE-A, CA-H, RR-C, LH-M, LG-L, GC-O, AG-E, IC-H, AM-H, ML-C, NH-P, JG-K, MR-V, DT-V, CC-R, FM-L, JP-G, AM-R, AA-S, BS-D, MG-R, LM-P, GV-A, MM-R, OS-R, HR-V, JR-B, and AH-M: resources. SJ-M: writing&#x2014;original draft preparation. SJ-M, AH-M, and JM-A: writing&#x2014;review and editing and supervision. SJ-M, JC-E, and JM-A: funding acquisition. All authors reviewed the final manuscript and read and approved the submitted version.</p>
</sec>
<sec id="s8" sec-type="funding-information">
<title>Funding</title>
<p>This work was supported by the Consejo Nacional de Ciencia y Tecnolog&#xed;a (CONACyT), Investigaci&#xf3;n en Fronteras de la Ciencia (IFC)-2016-01-2119, PDCPN2013-01-215726, CB-2015-1-258042, FIS/IMSS/PROT/1548, FONCICYT/37/2018, FIS/IMSS/PROT/1782, and FORDECYT-PRONACES-377883-2020. We also thank the financial support from the National Institute of Genomic Medicine (01/2018/I, 19/2019/I).</p>
</sec>
<sec id="s9" sec-type="COI-statement">
<title>Conflict of Interest</title>
<p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>
</sec>
<sec id="s10" sec-type="disclaimer">
<title>Publisher&#x2019;s Note</title>
<p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p>
</sec>
</body>
<back>
<ack>
<title>Acknowledgments</title>
<p>We thank to Dr. Catherine Metayer from the California, Berkeley School of Public Health, USA, because of their donation of saliva kits used to perform this project. We thank all patients and people from the institutions involved in the clinical management of our cases.</p>
</ack>
<sec id="s11" sec-type="supplementary-material">
<title>Supplementary Material</title>
<p>The Supplementary Material for this article can be found online at: <ext-link ext-link-type="uri" xlink:href="https://www.frontiersin.org/articles/10.3389/fonc.2021.762063/full#supplementary-material">https://www.frontiersin.org/articles/10.3389/fonc.2021.762063/full#supplementary-material</ext-link>
</p>
<supplementary-material xlink:href="DataSheet_1.docx" id="SM1" mimetype="application/vnd.openxmlformats-officedocument.wordprocessingml.document"/>
</sec>
<ref-list>
<title>References</title>
<ref id="B1">
<label>1</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>P&#xe9;rez-Saldivar</surname> <given-names>ML</given-names>
</name>
<name>
<surname>Fajardo-Guti&#xe9;rrez</surname> <given-names>A</given-names>
</name>
<name>
<surname>Bern&#xe1;ldez-R&#xed;os</surname> <given-names>R</given-names>
</name>
<name>
<surname>Mart&#xed;nez-Avalos</surname> <given-names>A</given-names>
</name>
<name>
<surname>Medina-Sanson</surname> <given-names>A</given-names>
</name>
<name>
<surname>Espinosa-Hern&#xe1;ndez</surname> <given-names>L</given-names>
</name>
<etal/>
</person-group>. <article-title>Childhood Acute Leukemias are Frequent in Mexico City: Descriptive Epidemiology</article-title>. <source>BMC Cancer</source> (<year>2011</year>) <volume>11</volume>:<fpage>355</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1186/1471-2407-11-355</pub-id>
</citation>
</ref>
<ref id="B2">
<label>2</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jim&#xe9;nez-Hern&#xe1;ndez</surname> <given-names>E</given-names>
</name>
<name>
<surname>Jaimes-Reyes</surname> <given-names>EZ</given-names>
</name>
<name>
<surname>Arellano-Galindo</surname> <given-names>J</given-names>
</name>
<name>
<surname>Garc&#xed;a-Jim&#xe9;nez</surname> <given-names>X</given-names>
</name>
<name>
<surname>Tiznado-Garc&#xed;a</surname> <given-names>HM</given-names>
</name>
<name>
<surname>Due&#xf1;as-Gonz&#xe1;lez</surname> <given-names>MT</given-names>
</name>
<etal/>
</person-group>. <article-title>Survival of Mexican Children With Acute Lymphoblastic Leukaemia Under Treatment With the Protocol From the Dana-Farber Cancer Institute 00-01</article-title>. <source>BioMed Res Int</source> (<year>2015</year>) <volume>2015</volume>:<elocation-id>576950</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.1155/2015/576950</pub-id>
</citation>
</ref>
<ref id="B3">
<label>3</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mart&#xed;n-Trejo</surname> <given-names>JA</given-names>
</name>
<name>
<surname>N&#xfa;&#xf1;ez-Enr&#xed;quez</surname> <given-names>JC</given-names>
</name>
<name>
<surname>Fajardo-Guti&#xe9;rrez</surname> <given-names>A</given-names>
</name>
<name>
<surname>Medina-Sans&#xf3;n</surname> <given-names>A</given-names>
</name>
<name>
<surname>Flores-Lujano</surname> <given-names>J</given-names>
</name>
<name>
<surname>Jim&#xe9;nez-Hern&#xe1;ndez</surname> <given-names>E</given-names>
</name>
<etal/>
</person-group>. <article-title>Early Mortality in Children With Acute Lymphoblastic Leukemia in a Developing Country: The Role of Malnutrition at Diagnosis. A Multicenter Cohort MIGICCL Study</article-title>. <source>Leuk Lymphoma</source> (<year>2017</year>) <volume>58</volume>(<issue>4</issue>):<fpage>898</fpage>&#x2013;<lpage>908</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1080/10428194.2016.1219904</pub-id>
</citation>
</ref>
<ref id="B4">
<label>4</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hunger</surname> <given-names>SP</given-names>
</name>
<name>
<surname>Mullighan</surname> <given-names>CG</given-names>
</name>
</person-group>. <article-title>Acute Lymphoblastic Leukemia in Children</article-title>. <source>N Engl J Med</source> (<year>2015</year>) <volume>373</volume>(<issue>16</issue>):<page-range>1541&#x2013;52</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1056/NEJMra1400972</pub-id>
</citation>
</ref>
<ref id="B5">
<label>5</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jim&#xe9;nez-Hern&#xe1;ndez</surname> <given-names>E</given-names>
</name>
<name>
<surname>Duarte-Rodr&#xed;guez</surname> <given-names>DA</given-names>
</name>
<name>
<surname>N&#xfa;&#xf1;ez-Enriquez</surname> <given-names>JC</given-names>
</name>
<name>
<surname>Flores-Lujano</surname> <given-names>J</given-names>
</name>
<name>
<surname>Mart&#xed;n-Trejo</surname> <given-names>JA</given-names>
</name>
<name>
<surname>Espinoza-Hern&#xe1;ndez</surname> <given-names>LE</given-names>
</name>
<etal/>
</person-group>. <article-title>Maternal and Paternal Ages at Conception of Index Child and Risk of Childhood Acute Leukaemia: A Multicentre Case-Control Study in Greater Mexico City</article-title>. <source>Cancer Epidemiol</source> (<year>2020</year>) <volume>67</volume>:<elocation-id>101731</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.canep.2020.101731</pub-id>
</citation>
</ref>
<ref id="B6">
<label>6</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Medina-Sanson</surname> <given-names>A</given-names>
</name>
<name>
<surname>N&#xfa;&#xf1;ez-Enr&#xed;quez</surname> <given-names>JC</given-names>
</name>
<name>
<surname>Hurtado-Cordova</surname> <given-names>E</given-names>
</name>
<name>
<surname>P&#xe9;rez-Saldivar</surname> <given-names>ML</given-names>
</name>
<name>
<surname>Mart&#xed;nez-Garc&#xed;a</surname> <given-names>A</given-names>
</name>
<name>
<surname>Jim&#xe9;nez-Hern&#xe1;ndez</surname> <given-names>E</given-names>
</name>
<etal/>
</person-group>. <article-title>Genotype-Environment Interaction Analysis of NQO1, CYP2E1, and NAT2 Polymorphisms and the Risk of Childhood Acute Lymphoblastic Leukemia: A Report From the Mexican Interinstitutional Group for the Identification of the Causes of Childhood Leukemia</article-title>. <source>Front Oncol</source> (<year>2020</year>) <volume>10</volume>:<elocation-id>571869</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.3389/fonc.2020.571869</pub-id>
</citation>
</ref>
<ref id="B7">
<label>7</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Xu</surname> <given-names>H</given-names>
</name>
<name>
<surname>Cheng</surname> <given-names>C</given-names>
</name>
<name>
<surname>Devidas</surname> <given-names>M</given-names>
</name>
<name>
<surname>Pei</surname> <given-names>D</given-names>
</name>
<name>
<surname>Fan</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Yang</surname> <given-names>W</given-names>
</name>
<etal/>
</person-group>. <article-title>ARID5B Genetic Polymorphisms Contribute to Racial Disparities in the Incidence and Treatment Outcome of Childhood Acute Lymphoblastic Leukemia</article-title>. <source>J Clin Oncol</source> (<year>2012</year>) <volume>30</volume>(<issue>7</issue>):<page-range>751&#x2013;7</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1200/JCO.2011.38.0345</pub-id>
</citation>
</ref>
<ref id="B8">
<label>8</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gutierrez-Camino</surname> <given-names>A</given-names>
</name>
<name>
<surname>Lopez-Lopez</surname> <given-names>E</given-names>
</name>
<name>
<surname>Martin-Guerrero</surname> <given-names>I</given-names>
</name>
<name>
<surname>Pi&#xf1;an</surname> <given-names>MA</given-names>
</name>
<name>
<surname>Garcia-Miguel</surname> <given-names>P</given-names>
</name>
<name>
<surname>Sanchez-Toledo</surname> <given-names>J</given-names>
</name>
<etal/>
</person-group>. <article-title>Noncoding RNA-Related Polymorphisms in Pediatric Acute Lymphoblastic Leukemia Susceptibility</article-title>. <source>Pediatr Res</source> (<year>2014</year>) <volume>75</volume>(<issue>6</issue>):<page-range>767&#x2013;73</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/pr.2014.43</pub-id>
</citation>
</ref>
<ref id="B9">
<label>9</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jemimah Devanandan</surname> <given-names>H</given-names>
</name>
<name>
<surname>Venkatesan</surname> <given-names>V</given-names>
</name>
<name>
<surname>Scott</surname> <given-names>JX</given-names>
</name>
<name>
<surname>Magatha</surname> <given-names>LS</given-names>
</name>
<name>
<surname>Durairaj Paul</surname> <given-names>SF</given-names>
</name>
<name>
<surname>Koshy</surname> <given-names>T</given-names>
</name>
</person-group>. <article-title>MicroRNA 146a Polymorphisms and Expression in Indian Children With Acute Lymphoblastic Leukemia</article-title>. <source>Lab Med</source> (<year>2019</year>) <volume>50</volume>(<issue>3</issue>):<page-range>249&#x2013;53</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1093/labmed/lmy074</pub-id>
</citation>
</ref>
<ref id="B10">
<label>10</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>James</surname> <given-names>AR</given-names>
</name>
<name>
<surname>Schroeder</surname> <given-names>MP</given-names>
</name>
<name>
<surname>Neumann</surname> <given-names>M</given-names>
</name>
<name>
<surname>Bastian</surname> <given-names>L</given-names>
</name>
<name>
<surname>Eckert</surname> <given-names>C</given-names>
</name>
<name>
<surname>G&#xf6;kbuget</surname> <given-names>N</given-names>
</name>
<etal/>
</person-group>. <article-title>Long non-Coding RNAs Defining Major Subtypes of B Cell Precursor Acute Lymphoblastic Leukemia</article-title>. <source>J Hematol Oncol</source> (<year>2019</year>) <volume>12</volume>(<issue>1</issue>):<fpage>8</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1186/s13045-018-0692-3</pub-id>
</citation>
</ref>
<ref id="B11">
<label>11</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liu</surname> <given-names>B</given-names>
</name>
<name>
<surname>Li</surname> <given-names>J</given-names>
</name>
<name>
<surname>Cairns</surname> <given-names>MJ</given-names>
</name>
</person-group>. <article-title>Identifying miRNAs, Targets and Functions</article-title>. <source>Brief Bioinform</source> (<year>2014</year>) <volume>15</volume>(<issue>1</issue>):<fpage>1</fpage>&#x2013;<lpage>19</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1093/bib/bbs075</pub-id>
</citation>
</ref>
<ref id="B12">
<label>12</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dzikiewicz-Krawczyk</surname> <given-names>A</given-names>
</name>
<name>
<surname>Macieja</surname> <given-names>A</given-names>
</name>
<name>
<surname>Ma&#x142;y</surname> <given-names>E</given-names>
</name>
<name>
<surname>Januszkiewicz-Lewandowska</surname> <given-names>D</given-names>
</name>
<name>
<surname>Mosor</surname> <given-names>M</given-names>
</name>
<name>
<surname>Fichna</surname> <given-names>M</given-names>
</name>
<etal/>
</person-group>. <article-title>Polymorphisms in microRNA Target Sites Modulate Risk of Lymphoblastic and Myeloid Leukemias and Affect microRNA Binding</article-title>. <source>J Hematol Oncol</source> (<year>2014</year>) <volume>7</volume>:<fpage>43</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1186/1756-8722-7-43</pub-id>
</citation>
</ref>
<ref id="B13">
<label>13</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rakmanee</surname> <given-names>S</given-names>
</name>
<name>
<surname>Pakakasama</surname> <given-names>S</given-names>
</name>
<name>
<surname>Hongeng</surname> <given-names>S</given-names>
</name>
<name>
<surname>Sanguansin</surname> <given-names>S</given-names>
</name>
<name>
<surname>Thongmee</surname> <given-names>A</given-names>
</name>
<name>
<surname>Pongstaporn</surname> <given-names>W</given-names>
</name>
</person-group>. <article-title>Increased Risk of Thai Childhood Acute Lymphoblastic Leukemia With the MiR196a2 T&gt;C Polymorphism</article-title>. <source>Asian Pac J Cancer Prev</source> (<year>2017</year>) <volume>18</volume>(<issue>4</issue>):<page-range>1117&#x2013;20</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.22034/APJCP.2017.18.4.1117</pub-id>
</citation>
</ref>
<ref id="B14">
<label>14</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Duan</surname> <given-names>R</given-names>
</name>
<name>
<surname>Pak</surname> <given-names>C</given-names>
</name>
<name>
<surname>Jin</surname> <given-names>P</given-names>
</name>
</person-group>. <article-title>Single Nucleotide Polymorphism Associated With Mature miR-125a Alters the Processing of pri-miRNA</article-title>. <source>Hum Mol Genet</source> (<year>2007</year>) <volume>16</volume>(<issue>9</issue>):<page-range>1124&#x2013;31</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1093/hmg/ddm062</pub-id>
</citation>
</ref>
<ref id="B15">
<label>15</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sun</surname> <given-names>G</given-names>
</name>
<name>
<surname>Yan</surname> <given-names>J</given-names>
</name>
<name>
<surname>Noltner</surname> <given-names>K</given-names>
</name>
<name>
<surname>Feng</surname> <given-names>J</given-names>
</name>
<name>
<surname>Li</surname> <given-names>H</given-names>
</name>
<name>
<surname>Sarkis</surname> <given-names>DA</given-names>
</name>
<etal/>
</person-group>. <article-title>SNPs in Human miRNA Genes Affect Biogenesis and Function</article-title>. <source>RNA</source> (<year>2009</year>) <volume>15</volume>(<issue>9</issue>):<page-range>1640&#x2013;51</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1261/rna.1560209</pub-id>
</citation>
</ref>
<ref id="B16">
<label>16</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Duyu</surname> <given-names>M</given-names>
</name>
<name>
<surname>Durmaz</surname> <given-names>B</given-names>
</name>
<name>
<surname>Gunduz</surname> <given-names>C</given-names>
</name>
<name>
<surname>Vergin</surname> <given-names>C</given-names>
</name>
<name>
<surname>Yilmaz Karapinar</surname> <given-names>D</given-names>
</name>
<name>
<surname>Aksoylar</surname> <given-names>S</given-names>
</name>
<etal/>
</person-group>. <article-title>Prospective Evaluation of Whole Genome microRNA Expression Profiling in Childhood Acute Lymphoblastic Leukemia</article-title>. <source>BioMed Res Int</source> (<year>2014</year>) <volume>2014</volume>:<elocation-id>967585</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.1155/2014/967585</pub-id>
</citation>
</ref>
<ref id="B17">
<label>17</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zou</surname> <given-names>D</given-names>
</name>
<name>
<surname>Yin</surname> <given-names>J</given-names>
</name>
<name>
<surname>Ye</surname> <given-names>Z</given-names>
</name>
<name>
<surname>Zeng</surname> <given-names>Q</given-names>
</name>
<name>
<surname>Tian</surname> <given-names>C</given-names>
</name>
<name>
<surname>Wang</surname> <given-names>Y</given-names>
</name>
<etal/>
</person-group>. <article-title>Association Between the <italic>miR-146a</italic> Rs2910164 Polymorphism and Childhood Acute Lymphoblastic Leukemia Susceptibility in an Asian Population</article-title>. <source>Front Genet</source> (<year>2020</year>) <volume>11</volume>:<elocation-id>886</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.3389/fgene.2020.00886</pub-id>
</citation>
</ref>
<ref id="B18">
<label>18</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lian</surname> <given-names>H</given-names>
</name>
<name>
<surname>Wang</surname> <given-names>L</given-names>
</name>
<name>
<surname>Zhang</surname> <given-names>J</given-names>
</name>
</person-group>. <article-title>Increased Risk of Breast Cancer Associated With CC Genotype of Has-miR-146a Rs2910164 Polymorphism in Europeans</article-title>. <source>PloS One</source> (<year>2012</year>) <volume>7</volume>(<issue>2</issue>):<elocation-id>e31615</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.1371/journal.pone.0031615</pub-id>
</citation>
</ref>
<ref id="B19">
<label>19</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Alem&#xe1;n-&#xc1;vila</surname> <given-names>I</given-names>
</name>
<name>
<surname>Jim&#xe9;nez-Morales</surname> <given-names>M</given-names>
</name>
<name>
<surname>Beltr&#xe1;n-Ram&#xed;rez</surname> <given-names>O</given-names>
</name>
<name>
<surname>Barbosa-Cobos</surname> <given-names>RE</given-names>
</name>
<name>
<surname>Jim&#xe9;nez-Morales</surname> <given-names>S</given-names>
</name>
<name>
<surname>S&#xe1;nchez-Mu&#xf1;oz</surname> <given-names>F</given-names>
</name>
<etal/>
</person-group>. <article-title>Functional Polymorphisms in <italic>Pre-Mir146a</italic> and <italic>Pre-Mir499</italic> are Associated With Systemic Lupus Erythematosus But Not With Rheumatoid Arthritis or Graves&#x2019; Disease in Mexican Patients</article-title>. <source>Oncotarget</source> (<year>2017</year>) <volume>8</volume>(<issue>54</issue>):<page-range>91876&#x2013;86</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.18632/oncotarget.19621</pub-id>
</citation>
</ref>
<ref id="B20">
<label>20</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mi</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Ren</surname> <given-names>K</given-names>
</name>
<name>
<surname>Zou</surname> <given-names>J</given-names>
</name>
<name>
<surname>Bai</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Zhang</surname> <given-names>L</given-names>
</name>
<name>
<surname>Zuo</surname> <given-names>L</given-names>
</name>
<etal/>
</person-group>. <article-title>The Association Between Three Genetic Variants in MicroRNAs (Rs11614913, Rs2910164, Rs3746444) and Prostate Cancer Risk</article-title>. <source>Cell Physiol Biochem</source> (<year>2018</year>) <volume>48</volume>(<issue>1</issue>):<page-range>149&#x2013;57</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1159/000491671</pub-id>
</citation>
</ref>
<ref id="B21">
<label>21</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chansing</surname> <given-names>K</given-names>
</name>
<name>
<surname>Pakakasama</surname> <given-names>S</given-names>
</name>
<name>
<surname>Hongeng</surname> <given-names>S</given-names>
</name>
<name>
<surname>Thongmee</surname> <given-names>A</given-names>
</name>
<name>
<surname>Pongstaporn</surname> <given-names>W</given-names>
</name>
</person-group>. <article-title>Lack of Association Between the MiR146a Polymorphism and Susceptibility to Thai Childhood Acute Lymphoblastic Leukemia</article-title>. <source>Asian Pac J Cancer Prev</source> (<year>2016</year>) <volume>17</volume>(<issue>5</issue>):<page-range>2435&#x2013;8</page-range>.</citation>
</ref>
<ref id="B22">
<label>22</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yang</surname> <given-names>X</given-names>
</name>
<name>
<surname>Li</surname> <given-names>X</given-names>
</name>
<name>
<surname>Zhou</surname> <given-names>B</given-names>
</name>
</person-group>. <article-title>A Meta-Analysis of miR-499 Rs3746444 Polymorphism for Cancer Risk of Different Systems: Evidence From 65 Case-Control Studies</article-title>. <source>Front Physiol</source> (<year>2018</year>) <volume>9</volume>:<elocation-id>737</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.3389/fphys.2018.00737</pub-id>
</citation>
</ref>
<ref id="B23">
<label>23</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hasani</surname> <given-names>SS</given-names>
</name>
<name>
<surname>Hashemi</surname> <given-names>M</given-names>
</name>
<name>
<surname>Eskandari-Nasab</surname> <given-names>E</given-names>
</name>
<name>
<surname>Naderi</surname> <given-names>M</given-names>
</name>
<name>
<surname>Omrani</surname> <given-names>M</given-names>
</name>
<name>
<surname>Sheybani-Nasab</surname> <given-names>M</given-names>
</name>
</person-group>. <article-title>A Functional Polymorphism in the miR-146a Gene is Associated With the Risk of Childhood Acute Lymphoblastic Leukemia: A Preliminary Report</article-title>. <source>Tumour Biol</source> (<year>2014</year>) <volume>35</volume>(<issue>1</issue>):<page-range>219&#x2013;25</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1007/s13277-013-1027-1</pub-id>
</citation>
</ref>
<ref id="B24">
<label>24</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tong</surname> <given-names>N</given-names>
</name>
<name>
<surname>Xu</surname> <given-names>B</given-names>
</name>
<name>
<surname>Shi</surname> <given-names>D</given-names>
</name>
<name>
<surname>Du</surname> <given-names>M</given-names>
</name>
<name>
<surname>Li</surname> <given-names>X</given-names>
</name>
<name>
<surname>Sheng</surname> <given-names>X</given-names>
</name>
<etal/>
</person-group>. <article-title>Hsa-miR-196a2 Polymorphism Increases the Risk of Acute Lymphoblastic Leukemia in Chinese Children</article-title>. <source>Mutat Res</source> (<year>2014</year>) <volume>759</volume>:<fpage>16</fpage>&#x2013;<lpage>21</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.mrfmmm.2013.11.004</pub-id>
</citation>
</ref>
<ref id="B25">
<label>25</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pei</surname> <given-names>JS</given-names>
</name>
<name>
<surname>Chang</surname> <given-names>WS</given-names>
</name>
<name>
<surname>Hsu</surname> <given-names>PC</given-names>
</name>
<name>
<surname>Chen</surname> <given-names>CC</given-names>
</name>
<name>
<surname>Chin</surname> <given-names>YT</given-names>
</name>
<name>
<surname>Huang</surname> <given-names>TL</given-names>
</name>
<etal/>
</person-group>. <article-title>Significant Association Between the MiR146a Genotypes and Susceptibility to Childhood Acute Lymphoblastic Leukemia in Taiwan</article-title>. <source>Cancer Genomics Proteomics</source> (<year>2020</year>) <volume>17</volume>(<issue>2</issue>):<page-range>175&#x2013;80</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.21873/cgp.20178</pub-id>
</citation>
</ref>
<ref id="B26">
<label>26</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>de Souza</surname> <given-names>TP</given-names>
</name>
<name>
<surname>de Carvalho</surname> <given-names>DC</given-names>
</name>
<name>
<surname>Wanderley</surname> <given-names>AV</given-names>
</name>
<name>
<surname>Fernandes</surname> <given-names>SM</given-names>
</name>
<name>
<surname>Rodrigues</surname> <given-names>JCG</given-names>
</name>
<name>
<surname>Cohen-Paes</surname> <given-names>A</given-names>
</name>
<etal/>
</person-group>. <article-title>Influence of Variants of the <italic>Drosha</italic>, <italic>Mir499a</italic>, and <italic>Mir938</italic> Genes on Susceptibility to Acute Lymphoblastic Leukemia in an Admixed Population From the Brazilian Amazon</article-title>. <source>Am J Transl Res</source> (<year>2020</year>) <volume>12</volume>(<issue>12</issue>):<page-range>8216&#x2013;24</page-range>.</citation>
</ref>
<ref id="B27">
<label>27</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Moore</surname> <given-names>JH</given-names>
</name>
<name>
<surname>Gilbert</surname> <given-names>JC</given-names>
</name>
<name>
<surname>Tsai</surname> <given-names>CT</given-names>
</name>
<name>
<surname>Chiang</surname> <given-names>FT</given-names>
</name>
<name>
<surname>Holden</surname> <given-names>T</given-names>
</name>
<name>
<surname>Barney</surname> <given-names>N</given-names>
</name>
<etal/>
</person-group>. <article-title>A Flexible Computational Framework for Detecting, Characterizing, and Interpreting Statistical Patterns of Epistasis in Genetic Studies of Human Disease Susceptibility</article-title>. <source>J Theor Biol</source> (<year>2006</year>) <volume>241</volume>(<issue>2</issue>):<page-range>252&#x2013;61</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.jtbi.2005.11.036</pub-id>
</citation>
</ref>
<ref id="B28">
<label>28</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chen</surname> <given-names>C</given-names>
</name>
<name>
<surname>Yan</surname> <given-names>Y</given-names>
</name> <name>
<surname>Liu</surname> <given-names>X</given-names>
</name>
</person-group>. <article-title>microRNA-612 Is Downregulated by Platelet-Derived Growth Factor-BB Treatment and has Inhibitory Effects on Vascular Smooth Muscle Cell Proliferation and Migration <italic>via</italic> Directly Targeting AKT2</article-title>. <source>Exp Ther Med</source> (<year>2018</year>) <volume>15</volume>(<issue>1</issue>):<page-range>159&#x2013;65</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.3892/etm.2017.5428</pub-id>
</citation>
</ref>
<ref id="B29">
<label>29</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Xie</surname> <given-names>M</given-names>
</name>
<name>
<surname>Yang</surname> <given-names>A</given-names>
</name>
<name>
<surname>Ma</surname> <given-names>J</given-names>
</name>
<name>
<surname>Wu</surname> <given-names>M</given-names>
</name>
<name>
<surname>Xu</surname> <given-names>H</given-names>
</name>
<name>
<surname>Wu</surname> <given-names>K</given-names>
</name>
<etal/>
</person-group>. <article-title>Akt2 Mediates Glucocorticoid Resistance in Lymphoid Malignancies Through FoxO3a/Bim Axis and Serves as a Direct Target for Resistance Reversal</article-title>. <source>Cell Death Dis</source> (<year>2019</year>) <volume>9</volume>(<issue>10</issue>):<fpage>1013</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/s41419-018-1043-6</pub-id>
</citation>
</ref>
<ref id="B30">
<label>30</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liu</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Lu</surname> <given-names>LL</given-names>
</name>
<name>
<surname>Wen</surname> <given-names>D</given-names>
</name>
<name>
<surname>Liu</surname> <given-names>DL</given-names>
</name>
<name>
<surname>Dong</surname> <given-names>LL</given-names>
</name>
<name>
<surname>Gao</surname> <given-names>DM</given-names>
</name>
<etal/>
</person-group>. <article-title>MiR-612 Regulates Invadopodia of Hepatocellular Carcinoma by HADHA-Mediated Lipid Reprogramming</article-title>. <source>J Hematol Oncol</source> (<year>2020</year>) <volume>13</volume>(<issue>1</issue>):<fpage>12</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1186/s13045-019-0841-3</pub-id>
</citation>
</ref>
<ref id="B31">
<label>31</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Taganov</surname> <given-names>KD</given-names>
</name>
<name>
<surname>Boldin</surname> <given-names>MP</given-names>
</name>
<name>
<surname>Chang</surname> <given-names>KJ</given-names>
</name>
<name>
<surname>Baltimore</surname> <given-names>D</given-names>
</name>
</person-group>. <article-title>NF-kappaB-Dependent Induction of microRNA miR-146, an Inhibitor Targeted to Signaling Proteins of Innate Immune Responses</article-title>. <source>Proc Natl Acad Sci U S A</source> (<year>2006</year>) <volume>103</volume>(<issue>33</issue>):<page-range>12481&#x2013;6</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1073/pnas.0605298103</pub-id>
</citation>
</ref>
<ref id="B32">
<label>32</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yan</surname> <given-names>W</given-names>
</name>
<name>
<surname>Gao</surname> <given-names>X</given-names>
</name>
<name>
<surname>Zhang</surname> <given-names>S</given-names>
</name>
</person-group>. <article-title>Association of miR-196a2 Rs11614913 and miR-499 Rs3746444 Polymorphisms With Cancer Risk: A Meta-Analysis</article-title>. <source>Oncotarget</source> (<year>2017</year>) <volume>8</volume>(<issue>69</issue>):<page-range>114344&#x2013;59</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.18632/oncotarget.22547</pub-id>
</citation>
</ref>
<ref id="B33">
<label>33</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hu</surname> <given-names>Z</given-names>
</name>
<name>
<surname>Liang</surname> <given-names>J</given-names>
</name>
<name>
<surname>Wang</surname> <given-names>Z</given-names>
</name>
<name>
<surname>Tian</surname> <given-names>T</given-names>
</name>
<name>
<surname>Zhou</surname> <given-names>X</given-names>
</name>
<name>
<surname>Chen</surname> <given-names>J</given-names>
</name>
<etal/>
</person-group>. <article-title>Common Genetic Variants in pre-microRNAs Were Associated With Increased Risk of Breast Cancer in Chinese Women</article-title>. <source>Hum Mutat</source> (<year>2009</year>) <volume>30</volume>(<issue>1</issue>):<fpage>79</fpage>&#x2013;<lpage>84</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1002/humu.20837</pub-id>
</citation>
</ref>
<ref id="B34">
<label>34</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yang</surname> <given-names>S</given-names>
</name>
<name>
<surname>Zheng</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Zhou</surname> <given-names>L</given-names>
</name>
<name>
<surname>Jin</surname> <given-names>J</given-names>
</name>
<name>
<surname>Deng</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Yao</surname> <given-names>J</given-names>
</name>
<etal/>
</person-group>. <article-title>miR-499 Rs3746444 and miR-196a-2 Rs11614913 Are Associated With the Risk of Glioma, But Not the Prognosis</article-title>. <source>Mol Ther Nucleic Acids</source> (<year>2020</year>) <volume>22</volume>:<page-range>340&#x2013;51</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.omtn.2020.08.038</pub-id>
</citation>
</ref>
<ref id="B35">
<label>35</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>He</surname> <given-names>S</given-names>
</name>
<name>
<surname>Li</surname> <given-names>Z</given-names>
</name>
<name>
<surname>Yu</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Zeng</surname> <given-names>Q</given-names>
</name>
<name>
<surname>Cheng</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Ji</surname> <given-names>W</given-names>
</name>
<etal/>
</person-group>. <article-title>Exosomal miR-499a-5p Promotes Cell Proliferation, Migration and EMT <italic>via</italic> mTOR Signaling Pathway in Lung Adenocarcinoma</article-title>. <source>Exp Cell Res</source> (<year>2019</year>) <volume>379</volume>(<issue>2</issue>):<page-range>203&#x2013;13</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.yexcr.2019.03.035</pub-id>
</citation>
</ref>
<ref id="B36">
<label>36</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shen</surname> <given-names>J</given-names>
</name>
<name>
<surname>Ambrosone</surname> <given-names>CB</given-names>
</name>
<name>
<surname>DiCioccio</surname> <given-names>RA</given-names>
</name>
<name>
<surname>Odunsi</surname> <given-names>K</given-names>
</name>
<name>
<surname>Lele</surname> <given-names>SB</given-names>
</name>
<name>
<surname>Zhao</surname> <given-names>H</given-names>
</name>
</person-group>. <article-title>A Functional Polymorphism in the miR-146a Gene and Age of Familial Breast/Ovarian Cancer Diagnosis</article-title>. <source>Carcinogenesis</source> (<year>2008</year>) <volume>29</volume>(<issue>10</issue>):<page-range>1963&#x2013;6</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1093/carcin/bgn172</pub-id>
</citation>
</ref>
<ref id="B37">
<label>37</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Saki</surname> <given-names>N</given-names>
</name>
<name>
<surname>Abroun</surname> <given-names>S</given-names>
</name>
<name>
<surname>Soleimani</surname> <given-names>M</given-names>
</name>
<name>
<surname>Mortazavi</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Kaviani</surname> <given-names>S</given-names>
</name>
<name>
<surname>Arefian</surname> <given-names>E</given-names>
</name>
</person-group>. <article-title>The Roles of miR-146a in the Differentiation of Jurkat T-Lymphoblasts</article-title>. <source>Hematology</source> (<year>2014</year>) <volume>19</volume>(<issue>3</issue>):<page-range>141&#x2013;7</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1179/1607845413Y.0000000105</pub-id>
</citation>
</ref>
<ref id="B38">
<label>38</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yan</surname> <given-names>W</given-names>
</name>
<name>
<surname>Guo</surname> <given-names>H</given-names>
</name>
<name>
<surname>Suo</surname> <given-names>F</given-names>
</name>
<name>
<surname>Han</surname> <given-names>C</given-names>
</name>
<name>
<surname>Zheng</surname> <given-names>H</given-names>
</name>
<name>
<surname>Chen</surname> <given-names>T</given-names>
</name>
</person-group>. <article-title>The Effect of miR-146a on STAT1 Expression and Apoptosis in Acute Lymphoblastic Leukemia Jurkat Cells</article-title>. <source>Oncol Lett</source> (<year>2017</year>) <volume>13</volume>(<issue>1</issue>):<page-range>151&#x2013;4</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.3892/ol.2016.5395</pub-id>
</citation>
</ref>
<ref id="B39">
<label>39</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname> <given-names>L</given-names>
</name>
<name>
<surname>Zhang</surname> <given-names>H</given-names>
</name>
<name>
<surname>Lei</surname> <given-names>D</given-names>
</name>
</person-group>. <article-title>microRNA-146a Promotes Growth of Acute Leukemia Cells by Downregulating Ciliary Neurotrophic Factor Receptor and Activating JAK2/STAT3 Signaling</article-title>. <source>Yonsei Med J</source> (<year>2019</year>) <volume>60</volume>(<issue>10</issue>):<page-range>924&#x2013;34</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.3349/ymj.2019.60.10.924</pub-id>
</citation>
</ref>
<ref id="B40">
<label>40</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Su</surname> <given-names>YL</given-names>
</name>
<name>
<surname>Wang</surname> <given-names>X</given-names>
</name>
<name>
<surname>Mann</surname> <given-names>M</given-names>
</name>
<name>
<surname>Adamus</surname> <given-names>TP</given-names>
</name>
<name>
<surname>Wang</surname> <given-names>D</given-names>
</name>
<name>
<surname>Moreira</surname> <given-names>DF</given-names>
</name>
<etal/>
</person-group>. <article-title>Myeloid Cell-Targeted miR-146a Mimic Inhibits NF-&#x3ba;b-Driven Inflammation and Leukemia Progression <italic>In Vivo</italic>
</article-title>. <source>Blood</source> (<year>2020</year>) <volume>135</volume>(<issue>3</issue>):<page-range>167&#x2013;80</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1182/blood.2019002045</pub-id>
</citation>
</ref>
<ref id="B41">
<label>41</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Stickel</surname> <given-names>N</given-names>
</name>
<name>
<surname>Hanke</surname> <given-names>K</given-names>
</name>
<name>
<surname>Marschner</surname> <given-names>D</given-names>
</name>
<name>
<surname>Prinz</surname> <given-names>G</given-names>
</name>
<name>
<surname>K&#xf6;hler</surname> <given-names>M</given-names>
</name>
<name>
<surname>Melchinger</surname> <given-names>W</given-names>
</name>
<etal/>
</person-group>. <article-title>MicroRNA-146a Reduces MHC-II Expression <italic>via</italic> Targeting JAK/STAT Signaling in Dendritic Cells After Stem Cell Transplantation</article-title>. <source>Leukemia</source> (<year>2017</year>) <volume>31</volume>(<issue>12</issue>):<page-range>2732&#x2013;41</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/leu.2017.137</pub-id>
</citation>
</ref>
<ref id="B42">
<label>42</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Xue</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Yang</surname> <given-names>X</given-names>
</name>
<name>
<surname>Hu</surname> <given-names>S</given-names>
</name>
<name>
<surname>Kang</surname> <given-names>M</given-names>
</name>
<name>
<surname>Chen</surname> <given-names>J</given-names>
</name>
<name>
<surname>Fang</surname> <given-names>Y</given-names>
</name>
</person-group>. <article-title>A Genetic Variant in miR-100 is a Protective Factor of Childhood Acute Lymphoblastic Leukemia</article-title>. <source>Cancer Med</source> (<year>2019</year>) <volume>8</volume>(<issue>5</issue>):<page-range>2553&#x2013;60</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1002/cam4.2082</pub-id>
</citation>
</ref>
<ref id="B43">
<label>43</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Martin-Guerrero</surname> <given-names>I</given-names>
</name>
<name>
<surname>Gutierrez-Camino</surname> <given-names>A</given-names>
</name>
<name>
<surname>Lopez-Lopez</surname> <given-names>E</given-names>
</name>
<name>
<surname>Bilbao-Aldaiturriaga</surname> <given-names>N</given-names>
</name>
<name>
<surname>Pombar-Gomez</surname> <given-names>M</given-names>
</name>
<name>
<surname>Ardanaz</surname> <given-names>M</given-names>
</name>
<etal/>
</person-group>. <article-title>Genetic Variants in miRNA Processing Genes and pre-miRNAs are Associated With the Risk of Chronic Lymphocytic Leukemia</article-title>. <source>PloS One</source> (<year>2015</year>) <volume>10</volume>(<issue>3</issue>):<elocation-id>e0118905</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.1371/journal.pone.0118905</pub-id>
</citation>
</ref>
<ref id="B44">
<label>44</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hoffman</surname> <given-names>AE</given-names>
</name>
<name>
<surname>Zheng</surname> <given-names>T</given-names>
</name>
<name>
<surname>Yi</surname> <given-names>C</given-names>
</name>
<name>
<surname>Leaderer</surname> <given-names>D</given-names>
</name>
<name>
<surname>Weidhaas</surname> <given-names>J</given-names>
</name>
<name>
<surname>Slack</surname> <given-names>F</given-names>
</name>
<etal/>
</person-group>. <article-title>microRNA miR-196a-2 and Breast Cancer: A Genetic and Epigenetic Association Study and Functional Analysis</article-title>. <source>Cancer Res</source> (<year>2009</year>) <volume>69</volume>(<issue>14</issue>):<page-range>5970&#x2013;7</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1158/0008-5472.CAN-09-0236</pub-id>
</citation>
</ref>
<ref id="B45">
<label>45</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Luthra</surname> <given-names>R</given-names>
</name>
<name>
<surname>Singh</surname> <given-names>RR</given-names>
</name>
<name>
<surname>Luthra</surname> <given-names>MG</given-names>
</name>
<name>
<surname>Li</surname> <given-names>YX</given-names>
</name>
<name>
<surname>Hannah</surname> <given-names>C</given-names>
</name>
<name>
<surname>Romans</surname> <given-names>AM</given-names>
</name>
<etal/>
</person-group>. <article-title>MicroRNA-196a Targets Annexin A1: A microRNA-Mediated Mechanism of Annexin A1 Downregulation in Cancers</article-title>. <source>Oncogene</source> (<year>2008</year>) <volume>27</volume>(<issue>52</issue>):<page-range>6667&#x2013;78</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/onc.2008.256</pub-id>
</citation>
</ref>
<ref id="B46">
<label>46</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhao</surname> <given-names>H</given-names>
</name>
<name>
<surname>Xu</surname> <given-names>J</given-names>
</name>
<name>
<surname>Zhao</surname> <given-names>D</given-names>
</name>
<name>
<surname>Geng</surname> <given-names>M</given-names>
</name>
<name>
<surname>Ge</surname> <given-names>H</given-names>
</name>
<name>
<surname>Fu</surname> <given-names>L</given-names>
</name>
<etal/>
</person-group>. <article-title>Somatic Mutation of the SNP Rs11614913 and Its Association With Increased MIR 196a2 Expression in Breast Cancer</article-title>. <source>DNA Cell Biol</source> (<year>2016</year>) <volume>35</volume>(<issue>2</issue>):<page-range>81&#x2013;7</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1089/dna.2014.2785</pub-id>
</citation>
</ref>
<ref id="B47">
<label>47</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Choupani</surname> <given-names>J</given-names>
</name>
<name>
<surname>Nariman-Saleh-Fam</surname> <given-names>Z</given-names>
</name>
<name>
<surname>Saadatian</surname> <given-names>Z</given-names>
</name>
<name>
<surname>Ouladsahebmadarek</surname> <given-names>E</given-names>
</name>
<name>
<surname>Masotti</surname> <given-names>A</given-names>
</name>
<name>
<surname>Bastami</surname> <given-names>M</given-names>
</name>
</person-group>. <article-title>Association of Mir-196a-2 Rs11614913 and Mir-149 Rs2292832 Polymorphisms With Risk of Cancer: An Updated Meta-Analysis</article-title>. <source>Front Genet</source> (<year>2019</year>) <volume>10</volume>:<elocation-id>186</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.3389/fgene.2019.00186</pub-id>
</citation>
</ref>
<ref id="B48">
<label>48</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname> <given-names>T</given-names>
</name>
<name>
<surname>Niu</surname> <given-names>L</given-names>
</name>
<name>
<surname>Wu</surname> <given-names>L</given-names>
</name>
<name>
<surname>Gao</surname> <given-names>X</given-names>
</name>
<name>
<surname>Li</surname> <given-names>M</given-names>
</name>
<name>
<surname>Liu</surname> <given-names>W</given-names>
</name>
<etal/>
</person-group>. <article-title>A Functional Polymorphism in microRNA-196a2 is Associated With Increased Susceptibility to non-Hodgkin Lymphoma</article-title>. <source>Tumour Biol</source> (<year>2015</year>) <volume>36</volume>(<issue>5</issue>):<page-range>3279&#x2013;84</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1007/s13277-014-2957-y</pub-id>
</citation>
</ref>
<ref id="B49">
<label>49</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chen</surname> <given-names>CC</given-names>
</name>
<name>
<surname>Hsu</surname> <given-names>PC</given-names>
</name>
<name>
<surname>Shih</surname> <given-names>LC</given-names>
</name>
<name>
<surname>Hsu</surname> <given-names>YN</given-names>
</name>
<name>
<surname>Kuo</surname> <given-names>CC</given-names>
</name>
<name>
<surname>Chao</surname> <given-names>CY</given-names>
</name>
<etal/>
</person-group>. <article-title>MiR-196a-2 Genotypes Determine the Susceptibility and Early Onset of Childhood Acute Lymphoblastic</article-title>. <source>Leukemia Anticancer Res</source> (<year>2020</year>) <volume>40</volume>(<issue>8</issue>):<page-range>4465&#x2013;9</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.21873/anticanres.14451</pub-id>
</citation>
</ref>
<ref id="B50">
<label>50</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kim</surname> <given-names>HK</given-names>
</name>
<name>
<surname>Prokunina-Olsson</surname> <given-names>L</given-names>
</name>
<name>
<surname>Chanock</surname> <given-names>SJ</given-names>
</name>
</person-group>. <article-title>Common Genetic Variants in miR-1206 (8q24.2) and miR-612 (11q13.3) Affect Biogenesis of Mature miRNA Forms</article-title>. <source>PloS One</source> (<year>2012</year>) <volume>7</volume>(<issue>10</issue>):<elocation-id>e47454</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.1371/journal.pone.0047454</pub-id>
</citation>
</ref>
<ref id="B51">
<label>51</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Siyadat</surname> <given-names>P</given-names>
</name>
<name>
<surname>Ayatollahi</surname> <given-names>H</given-names>
</name>
<name>
<surname>Barati</surname> <given-names>M</given-names>
</name>
<name>
<surname>Sheikhi</surname> <given-names>M</given-names>
</name>
<name>
<surname>Shahidi</surname> <given-names>M</given-names>
</name>
</person-group>. <article-title>High Resolution Melting Analysis for Evaluation of Mir-612 (Rs12803915) Genetic Variant With Susceptibility to Pediatric Acute Lymphoblastic Leukemia</article-title>. <source>Rep Biochem Mol Biol</source> (<year>2021</year>) <volume>9</volume>(<issue>4</issue>):<page-range>385&#x2013;93</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.52547/rbmb.9.4.385</pub-id>
</citation>
</ref>
</ref-list>
</back>
</article>